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PREFACE 
The research presented in this thesis was done during my part-time PhD 
employment at Aalborg University Hospital in the years 2012-2017 in parallel with 
my specialist training in clinical biochemistry. The performed studies fall within the 
scope of two current target areas of research at Aalborg University Hospital, namely 
atrial fibrillation (AF) and extracellular vesicles (EVs). 
In 2009, a group of experienced researchers at Aalborg University Hospital, including 
my main supervisor, professor Søren Risom Kristensen and co-supervisor, professor 
Lars Hvilsted Rasmussen, formed the Atrial Fibrillation Study Group (AF Study Group) 
and established the project “Atrial Fibrillation – an epidemic. From genes and 
lifestyle to prevention and treatment”. In collaboration with 
international colleagues, the AF Study Group has since its foundation conducted 
studies on several aspects of atrial fibrillation and contiguous topics. 
In 2010 a burgeoning international interest in cell-derived EVs as mediators of 
various physiological and pathological bodily processes, including thrombosis, 
occasioned the arrangement of the first international meeting on “Microvesicles and 
Nanovesicles in Health and Disease” at Magdalen College, Oxford, UK, which I 
attended in company with professor Søren Risom Kristensen. One of the matters 
presented at the meeting, was the procoagulant potential of some EVs, among these 
subtypes exposing the procoagulant transmembrane protein termed tissue factor 
(TF). 
My PhD project is rooted in the AF Study Group, and its onset was an interest in the 
mechanisms causing thrombus formation in the left atrial appendage (LAA) of the 
heart and consequent thromboembolism and stroke as a common and serious 
complication in patients with AF. Anatomical and functional changes, including TF 
production, in the endocardium of the LAA in AF patients had been described in the 
literature. It was generally accepted that EVs were released from the plasma 
membrane of various cell types as a response to cell stress. Therefore, we nominated 
the potential release of procoagulant EVs from the LAA endothelium as one of the 
conceivable mechanisms of hypercoagulability in the LAA in AF patients. This 
hypothesis would become the objective for much of the work presented in this 
thesis, and challenges related to measurement of the heterogenous group of 
analytes collectively named EVs led us on a byway, which, for long stretches, would 
constitute the main route of the project. 
At the first annual meeting of the International Society of Extracellular Vesicles 
(ISEV), held in Gothenburg in April 2012, alongside a catching positivity towards the 
potential of EVs as future diagnostic and prognostic biomarkers, there was a 
common recognition of the necessity of considerable development in techniques for 
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EV isolation and analysis in order to fulfil that potential. As of 2017, the interest in 
EVs among researchers in various medical fields is still growing, and many 
associations between medical conditions and detected EVs described in the 
literature hold out interesting prospects of clinical diagnostic applications of EV 
analysis. However, technical limitations regarding the preparation and analysis of 
EVs in compositionally complex body fluids still hamper actual implementation of 
EVs as valuable analytes in a clinical setting. 
 
In our research, we have taken particular interest in EVs present in blood plasma. 
This has entailed considerations, and accordingly studies, on different factors 
causing variation in the results, not least the analytical interference caused by 
another type of particles present in this medium, namely lipoproteins. We hope that 
our investigations can contribute constructively to the body of knowledge in this 
field. 
I want to thank all my supervisors and all co-authors of the papers that form the basis 
for this thesis for their participation in this project. A special thanks to my main 
supervisor, Søren Risom Kristensen, for many constructive discussions, including a 
great amount of professional back-and-forth during the paper writing. Likewise, a 
special thanks to professor Jan Jesper Andreasen for including patients and making 
sample collection for study 4 possible. In that connection, I would also like to thank 
the other surgeons at the Department of Cardiothoracic Surgery along with the 
anesthesiologists and surgical nurses participating in sample collection in the 
operating room. Furthermore, I am grateful for the assistance that I received from 
several colleagues at the Department of Clinical Biochemistry regarding sample 
analysis, information technology, and taking over daily tasks during busy periods of 
the project. Finally, I want to thank my ever-supportive friends and family, 
particularly my wonderful wife, Katrine, and our cherished children, Mikkel, Mynte, 
Rasmus, and Mads, for being a solid source of encouragement and inspiration.  
 
Morten Mørk 
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READING GUIDE 
The thesis is based on four studies documented in each their paper. The list of papers 
is given on the following page. 
Then follows a background chapter, which is structured into three sections, each 
introducing one of the topics mentioned in the thesis title, namely “atrial 
fibrillation”, “thrombosis”, and “extracellular vesicles”. 
With the background chapter as a foundation, the ideas, approaches, and main 
findings of the four studies are collectively presented and discussed along with 
further perspectives, in the aims and hypotheses, methods, results, and discussion 
chapters. 
The content of the thesis is then summarized in an English and a Danish summary. 
Abbreviations used in this thesis are introduced in parantheses, and for look-up a full 
list of abbreviations is given prior to the list of references. 
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BACKGROUND 
ATRIAL FIBRILLATION 
DISCOVERY 
“When the pulse is irregular and tremulous and the beats occur at intervals, then 
the impulse of life fades; when the pulse is slender (smaller than feeble, but still 
perceptible, thin like a silk thread), then the impulse of life is small.”  
 
The quote above is from the ancient Chinese medical text, Huang Di Nei Jing Su 
Wen (“The Yellow Emperor’s Inner Canon”), written hundreds of years before 
common era1. Notes on health issues related to a palpable irregular pulse, most 
likely caused by the heart rhythm disorder, we now know as atrial fibrillation (AF), 
were also made by other prominent historical medical practitioners, including 
Moses Maimonides in the 12th century and William Stokes in the 19th century2. 
 
In the first decade of the 20th century, new technology paved the way for scientific 
advances in the understanding of the nature of the characteristic sustained, irregular 
pulse termed “pulsus irregularis perpetuus” by Heinrich Ewald Hering in 19033. 
At about the same time, James McKenzie used his self-invented clinical polygraph to 
record jugular pulse and demonstrated that the presystolic jugular “A wave” which, 
he stated, reflected auricular contraction, was not present in patients after they 
went from a normal to an irregular heart rhythm3. In 1901, Willem Einthoven had 
invented the string galvanometer for electrocardiography (ECG) for which he later 
received the Nobel Prize. This technology enabled Einthoven’s friend and colleague, 
Thomas Lewis, to record and closely study the electrical activity in the hearts of 
patients exhibiting the pulsus irregularis perpetuus, and in 1909 Lewis’ investigations 
led him to conclude that it was the result of what he then termed “auricular 
fibrillation”4. At the same time, Carl Julius Rothberger and Heinrich Winterberg 
performed similar ECG studies, and, together with Lewis, they have been 
acknowledged for the establishment of AF as a clinical identity5, forming the basis 
for the increasing amount of knowledge on this medically challenging condition that 
has been accumulated during the past hundred years and a bit. 
EPIDEMIOLOGY 
As AF is the most prevalent cardiac arrhythmia in the world6 and significantly 
increases the long-term all-cause mortality risk in both men and women7, it is not 
surprising that changes in the rhythm of the palpable pulse have caught the attention 
of several physicians, historically. When Lewis in his publication on the 
abovementioned investigations stated that the abnormal heart rhythm in question 
was a common condition5, although he did not base it on large epidemiological 
studies, he was certainly right. 
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On a global level, estimately 21 million men and 13 million women were living with 
AF in 20108. The prevalence is increasing, which can be attributed to improved ability 
to diagnose AF and to treat cardiac as well as noncardiac diseases9. The prevalence 
of AF increases markedly with age, and the numbers are expected to further increase 
significantly in the next decades along with the general increase in the age of the 
population and prevalence of conditions associated with AF8. In western countries, 
AF has been described as one of the most important health issues9, and in Europe 
and the USA one in four middle-aged persons are expected to develop AF8. As many 
patients with AF are asymptomatic when first diagnosed, this increasingly common 
condition has been described as a silent epidemic10. 
PATHOPHYSIOLOGY 
AF is a supraventricular tachycardia, and, as the term indicates, the condition implies 
rapid (tachy)11 heart action (cardia)12. This results from abnormal electrical activity 
from an anatomical location above (supra)13 the cardiac ventricles. 
The normal cardiac rhythm is a sinus rhythm, which implies that the electrical 
impulse that precedes and prompts each contraction of heart, arises in the sinus 
node, located in the right atrium of the heart. From there, the electrical signal 
propagates along a certain pathway which goes through the atria, the 
atrioventricular node, the bundle of His, the bundle branches, and the Purkinje 
fibers, providing for a coordinated contraction of the atria and after that the 
ventricles. In a heart with AF, disorganized electrical impulses arise in other areas of 
the atria than the sinus node. The multifactorial etiology of AF is not completely 
understood. Functional and structural changes in the atria, which can in the 
individual cases to a greater or lesser extent be attributed to clinical and genetic risk 
factors (see below), facilitate a complex interaction between rapidly firing atrial 
ectopic foci and an abnormal atrial tissue substrate which allows for perpetuation of 
the arrhythmia14,15. The resulting helter-skelter running electrical impulses do not 
provide effective contractions of the atria, which instead vibrate or “fibrillate”, and 
furthermore they hinder regular transmission of an impulse through the 
atrioventricular node and into the cardiac ventricles. Thus, apart from being 
frequent, the ventricular contractions in patients with ongoing AF are irregular, 
which can readily be detected by pulse palpation, as apparently noticed early by the 
Yellow Emperor, and documented in the characteristic ECG changes associated with 
AF, as demonstrated by Lewis. 
Clinical risk factors and associations 
Besides age, several cardiac and non-cardiac clinical risk factors of AF have been 
identified, including hypertension, diabetes mellitus, myocardial infarction, heart 
failure, valvular heart disease, left ventricular hypertrophy, cardiac surgery, 
hyperthyroidism, male sex, smoking, obesity, and alcohol use16. AF can also be 
provoked by rapid atrial activation which can be seen in patients with other 
supraventricular tachycardias, e.g. Wolff-Parkinson-White syndrome17. Moreover, 
 
15 
inflammation has been suggested to play an important role in initiation and 
maintenance of AF18. 
Genetic susceptibility 
Given that AF primarily occurs in older patients with one or more clinical risk factors 
it could be imagined that it would not have a strong genetic component. On the other 
hand, many older patients without any of these underlying clinical risk factors do 
develop AF, while others, suffering from several risk factors, maintain their sinus 
rhythm lifelong19, which may suggest some heritability. Indeed, a clear familial 
aggregation of lone AF, i.e. AF not accompanied by typical risk factors associated 
with AF20, has been demonstrated21,22. Genetic susceptibility can follow a 
monogenic, but more commonly follow a polygenic pattern23. Variants associated 
with AF have been described in genes coding for proteins involved in depolarisation 
and contraction of heart muscle cells and communication between cells, such as 
cardiac sodium channels, potassium channels, sarcoplasmatic reticulum ATPase, gap 
junction proteins, signaling molecules, and in genes related to inflammation23,24. 
CLASSIFICATION  
Various axes of classification can be used to describe AF in the particular cases. 
Considering patterns of presentation, duration, and spontaneous termination of 
episodes, AF can be divided into “first diagnosed AF”, “paroxysmal AF”, “persistent 
AF”, “long-standing AF”, “long-standing persistent AF”, and “permanent AF”. 
Applying other criteria, AF types such as “AF secondary to structural heart disease”, 
“focal AF”, “polygenic AF”, “monogenic AF”, “early-onset AF”, “post-operative AF”, 
“AF in athletes”, “lone AF” and “silent AF” have been defined8. Also, AF can be 
divided into “non-valvular AF” and “valvular AF”, the latter referring to AF with 
concurrent mitral stenosis or prosthetic heart valves25. 
CONSEQUENCES 
While many AF patients are asymptomatic, common symptoms of AF include 
palpitations, shortness of breath, lack of energy, weakness, lightheadedness, and 
chest pain26. The daily life of an AF patient can be markedly affected because of 
reduced physical capability27, and, based on questionnaires, the subjective quality of 
life has been demonstrated to be impaired28. 
As mentioned, apart from causing symptoms, AF increases mortality, in part 
attributed to undesirable interactions between AF and some of its predisposing 
factors. As mentioned, heart failure predisposes to AF, but, the other way around, 
AF can cause and worsen heart failure, which has to do with AF-induced structural 
cardiac remodeling and heart rate-related reduction of left ventricular ejection 
fraction. AF also impairs the prognosis in patients with valvular heart disease, and 
these two disorders can sustain each other8. Another consequence of the structural 
changes in the heart induced by AF is a tendency of return and maintenance of 
arrhythmia after initially time-limited episodes of AF. This self-perpetuating property 
of AF was first discovered in a study on goats by Wijffels et al., who introduced the 
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phrase “atrial fibrillation begets atrial fibrillation”29. The phenomenon has been 
linked to electrophysiological changes in the atria and pulmonary veins30 and may 
involve changes in the intrinsic cardiac autonomic nervous system31. 
The abovementioned symptoms and detrimental effects of AF can be counteracted 
by different therapeutic heart rate and rhythm control strategies, the specific choice 
in the individual case depending on factors such as duration of the arrhythmia, 
symptoms, and comorbidity. The options for rate control include beta-blockers, 
calcium channel blockers, cardiac glycosides, combination therapy, and, should all 
else fail, amiodarone. Strategies for rhythm control include pharmacological and 
electrical cardioversion. Surgical procedures for elimination of electrical pathways 
that facilitate the arrhythmia include catheter-based ablation as well as more 
invasive strategies8,17. 
However, as mentioned in the preface, the starting point of this PhD project was the 
interest in the mechanisms of another complication of AF, considered the most 
important one32, namely thromboembolism, which is a major cause of morbidity and 
mortality in AF patients, and which calls for a different category of therapy. This issue 
will be addressed in the next section, which is dedicated to thrombosis.  
THROMBOSIS 
Thrombosis can be regarded as a result of pathologic processes overwhelming the 
regulatory mechanisms of the vital physiological process termed hemostasis33. 
Therefore, in this section, a historical perspective on some early findings regarding 
thrombosis, will be followed by an introduction to the hemostatic system. Next, 
aspects of current knowledge on the mechanisms of thrombosis in general, and AF-
related thrombosis in particular, are presented. 
HISTORICAL PERSPECTIVE 
“When it coagulates within the pulse the blood ceases to circulate beneficially; when 
the blood coagulates within the foot it causes pains and chills” 
The statement above represents another quote from “The Yellow Emperor’s Inner 
Canon”34 and illustrates that, as was the case with the tendency of the palpable pulse 
to become irregular in some patients, the ability of the blood to transform from a 
fluid to a semisolid phase and the potential harmful consequences was observed 
already in ancient times. Other prominent personages from before common era, 
including Hippocrates and Aristotle, were aware of this phenomenon, which they 
regarded as being a result of cooling35. Galen of Pergamon (ca. 130-210 of the 
common era) was the first to use the term “thrombosis” (in Greek thrombos means 
clot) in relation to limb swelling36, plausibly caused by deep venous thrombosis. 
Much later, in the 17th century, Richard Wiseman described vein occlusion by blood 
clots36 and furthermore, in a note on varicose veins, he wrote that: 
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"It proceedeth from the restagnation of gross Blood, which being transmitted into 
the Veins, either by reason of the depending of the Part, or from some other pressure 
upon the Vessel, or else by its own grossness, proves unapt for Circulation. Then 
instead of continuing its current proportionably to the other Parts, it stops in the 
place and coagulates." 
(Richard Wiseman, 1676)37 
In this wording, Wiseman arguably described two of the three factors that would, 
centuries later, constitute “Virchows triad”, namely hypercoagulability and 
stasis36,37. The third component of this famous triad of factors, that theoretically 
underlie thrombosis, is endothelial injury37. Rudolph Virchow did not himself 
announce his own triad, but in the middle of the 19th century, based on experiments 
and observations mainly regarding thrombosis in the lungs and the legs, he 
formulated the statements, which were, about 100 years later, adapted by others in 
the conceptualization of Virchows triad. In a passage on the results of experiments 
on foreign bodies introduced into the lungs, which may have been important in 
forming the basis for Virchows triad, Virchow was, rather than thrombus inititation, 
in fact describing the consequences of a foreign body (which in vivo would be a 
pulmonary embolus) in the lungs: 
“In all cases the blood formed more or less extensive clots around the introduced 
body’. ‘…the list of possible consequences of the obstruction could be grouped into 
three categories; 
Phenomena due to the irritation of the vessel and its surroundings; 
Phenomena due to blood coagulation; 
Phenomena due to the interruption of the blood-stream” 
(Rudolph Virchow, 1856)37. 
 
The mentioned factors causing the phenomena were however, by Virchow himself, 
referred to as requisite conditions for thrombus propagation, which is obviously an 
essential element in thrombus formation. Further details on the plausible origin of 
the concept termed Virchows triad, which still today serves as an important part of 
the general comprehension of the causes of thrombosis, are thoroughly covered by 
Bagot et al.37 
THE HEMOSTATIC SYSTEM 
The hemostatic system, which is essential for maintenance of the circulatory system 
in humans, has evolved over millions of years, and provides for the arrest of bleeding 
by sealing defects and facilitating repair at sites of vascular injury38, which will occur 
many times during an individual’s lifetime39. The mechanisms by which hemostasis 
provides for the continuation of normal blood flow in the circulation involve complex 
interactions between cells and many extracellular components. As the cell type that 
constitutes the interior surface of blood vessels, endothelial cells play a major role 
in hemostasis, while leukocytes also take an active share, as hemostasis and 
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inflammation are to a great extent interwoven processes40,41. Platelets, which are 
circulating anuclear cell fragments derived from megakaryocytes in the bone 
marrow, are also essential for the hemostatic process. Endothelial cells, platelets, 
and leukocytes are all capable of releasing extracellular vesicles (EVs), which, owing 
to their potential procoagulant effect, may play an important role in thrombotic and 
hemostatic processes42. While EVs will be covered more detailedly in the next 
section, the mentioned cell types along with some hemostasis-related molecules are 
addressed in the following. Two important procoagulant proteins, namely TF and von 
Willebrand factor (vWF), which were among the objects of investigation in study 4 
of this PhD project, have been given their own subheadings. TF is also known as 
coagulation factor III (FIII) and thus represents one of the 13 coagulation factors 
involved in the coagulation cascade that leads to formation of a fibrin clot which is 
an essential element of the hemostasis process. 
Endothelial cells 
Under normal circumstances, the endothelium serves as an anticoagulant surface 
that lets the blood maintain its fluidity and as a barrier that separates the blood from 
the deeper layers of the vessel wall in which procoagulant agents such as collagen 
and TF are located38,43. The anticoagulant features of normal, intact endothelial cells 
include their secretion of nitric oxide (NO) and prostacyclin, which are platelet 
inhibitors and vasodilators, and the ectonucleotidase termed Cluster of 
Differentiation 39 (CD39), which metabolizes the platelet agonist adenosine 
diphosphate (ADP). Furthermore, endothelial cells express the anticoagulants tissue 
factor pathway inhibitor (TFPI), thrombomodulin (TM), endothelial cell protein C 
receptor (EPCR), heparin-like proteoglycans44, and plasminogen activators45. 
Endothelial cells are negatively charged and therefore possibly repel the likewise 
negatively charged platelets38. 
While the endothelium possesses many anticoagulant properties, it also has 
procoagulant features. Endothelial cells contain Weibel-Palade bodies, which are 
secretory organelles containing several proteins that enable endothelial cells to 
influence hemostasis and inflammation, including vWF, P-selectin46, and E-selectin38, 
the two last-mentioned mediating leukocyte and platelet rolling on endothelial cells 
prior to actual adhesion. The contents of the Weibel-Palade bodies can come into 
play in case of vascular insult or stimulation of endothelial cells by vasoactive agents 
such as thrombin (activated coagulation factor II (FIIa)), histamine, and bradykinin. 
Other factors that can stimulate endothelial cells to deviate from their 
nonthrombogenic protective behaviour, are hypoxia, fluid shear stress, oxidants, 
endotoxin, and inflammatory cytokines. It has been described that activated 
endothelial cells can synthesize TF and plasminogen activator inhibitor-1 (PAI-1)38. 
Leukocytes 
Like endothelial cells, quiescent leukocytes facilitate the maintenance of blood 
fluidity, e.g. by monocyte expression of anticoagulant factors such as EPCR, TM, and 
TFPI. However, exposed to certain stimuli, leukocytes can undergo transformation 
and release procoagulant mediators. One of the effects of leukocyte-released 
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cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 1b is 
downregulation of the expression of EPCR and TM. Monocytes represent the largest 
intravascular source of TF, which may also to a lesser extent be expressed by 
neutrophils and eosinophils47. Neutrophils also contain and release serine proteases 
that contribute to coagulation by activation of coagulation factor V, VIII, and X and 
degradation of the anticoagulant cofactors antithrombin, heparin cofactor II, and 
TFPI47. Another procoagulant feature of neutrophils is their ability to release 
neutrophil extracellular traps (NETs), and while there is little evidence that NETs play 
a significant role in normal hemostasis, they have been associated with arterial as 
well as venous thrombosis48, and will be further described under the heading 
“Mechanisms of thrombosis”.  
Platelets 
In a healthy adult each litre of blood typically contains between 150 and 400 billions 
of circulating platelets49. When flowing through normal, intact blood vessels, 
platelets are exposed to inhibitory signaling mechanisms from the endothelial cells 
which allow them to remain inactivated, not adhering to the vessel walls50. However, 
on their surface, platelets express multiple specific receptors such as Glycoprotein 
(GP) VI which can bind collagen, GPIbα which can bind vWF, P2Y12 which can bind 
ADP51, and GPIIb/IIIa which is a fibrinogen receptor, enabling the platelets to become 
quickly activated and exert their hemostatic functions upon vascular injury52. 
Platelets contain secretory granules, the most abundant type being the α-granule, 
which contains several types of proteins that play a role in inflammatory and 
hemostatic processes, including vWF, fibrinogen, and P-selectin53. Also, small 
amounts of TF have been identified in α-granules in platelets, potentially derived 
from monocyte-derived EVs incorporated after interaction with the platelet 
membrane via adhesion molecules54, while de novo synthesis of TF by platelets upon 
activation has also been described55. Platelets also contain so-called dense granules 
that contain ADP, adenosine triphosphate (ATP), and serotonin, which can along with 
thromboxane A2 (TXA2) be released from platelets and result in activation of other 
platelets56.  
Tissue factor 
TF, which has been established as the principal initiator of blood clotting in vivo57, is 
a glycoprotein which in its full-length form (flTF) is composed of 263 amino acids and 
exists in various cells throughout the body, including the adventitial cells that cover 
all blood vessels larger than capillaries and many types of epithelial cells that 
surround organs38. Thus being omnipresent in the deeper layers of the vasculature 
this crucial component of the blood coagulation system has been described as a 
“hemostatic envelope”58. When subendothelial TF is exposed to blood, it unites with 
blood coagulation factor VII in its inactive (FVII) and active (FVIIa) form thus forming 
the TF:FVIIa complex which is the most potent known activator of the coagulation 
cascade38 and this TF pathway has been described as the ‘prima ballerina’ in the 
initiation of coagulation57,59. In some cell types, such as fibroblasts, pericytes, and 
epithelial cells, TF is expressed constitutively, while in some vascular cells such as 
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smooth muscle cells and endothelial cells, which in their quiescent state do not 
express significant amounts of TF, expression of TF can reportedly be induced e.g. by 
inflammatory mediators38,54. The cell-associated flTF comprises a 21 amino acids long 
intracellular domain, a 23 amino acids long transmembrane domain, and a 219 
amino acids long extracellular domain. More recently, it was discovered that also a 
206 amino acids long isoform of TF, which is not membrane-integrated, exists60. This 
so-called alternatively spliced TF (asTF) is soluble in blood plasma and represents a 
type of blood-borne TF. Also flTF exists in a blood-borne form. TF can be expressed 
by monocytes, but circulating flTF has also been reported to be present in the 
membrane of EVs released from endothelial cells, smooth muscle cells, and 
platelets54. However, controversy exists regarding the range of cell types that are in 
fact able to release TF-bearing EVs61, which will be brought up again in the section 
on EVs. 
von Willebrand factor 
vWF is a glycoprotein synthesized in megakaryocytes and endothelial cells. In its 
monomeric form vWF contains 2050 amino acids, and through intracellular 
processing some of these monomers are assembled into large hemostatically active 
polymeric forms, which are stored in the Weibel-Palade bodies of endothelial cells 
and in the α-granules of platelets62. vWF is capable of binding to several types of 
collagen and other connective tissue components62, to which it will be exposed in 
case of vascular injury. As mentioned, vWF also has the ability to bind to GPIbα, but 
also other platelet receptors may be involved in vWF-mediated platelet recruitment 
to the injured part of the vessel wall63, which is an essential element of hemostasis. 
Moreover, vWF is a carrier protein for coagulation factor VIII (FVIII), and high levels 
of vWF induce high levels of FVIII63. The resting endothelial cells are believed to 
release some vWF constitutively, while larger amounts can be quickly released by 
exocytosis of Weibel-Palade bodies as a response to endothelial stimulation64. Such 
stimulated vWF release from endothelial cells can be induced by various activators, 
including hypoxia, trauma, shear stress, thrombin, fibrin, histamine, ADP, 
complement, and vascular endothelial growth factor (VEGF), while it can be inhibited 
by NO and hydrogen peroxide65. vWF secretion from platelets is predominantly or 
entirely stimulus-induced64. 
Platelet plug and fibrin clot formation 
When a blood vessel is injured, it constricts and thus limits the amount of blood that 
is shed from the circulation38. The amount of blood that does leak out comes into 
contact with subendothelial structures, which leads to a complex series of molecular 
events that provides for cessation of bleeding and repair of the vessel wall. 
As mentioned above, two essential elements of hemostasis are recruitment of 
platelets to the site of vessel wall injury and the course of the coagulation cascade. 
These two elements represent each their respective component of the traditional 
comprehension of hemostasis, in which the process is divided into primary and 
secondary hemostasis, although these two subprocesses, which take place 
simultaneously, are highly mechanistically intertwined43. 
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Platelet plug formation 
The many receptors that platelets carry on their surface, allow them to respond to 
the vascular injury, which leads to rapid platelet activation, secretion of platelet 
granule contents, platelet adherence to the subendothelial matrix, platelet 
aggregation, and eventually platelet plug formation that helps stop the bleeding49. 
The platelet activation comes about by several mechanisms, including platelet 
interaction with extracellular matrix components. Activated platelets themselves 
provide for the activation of other nearby platelets by release ADP, ATP, serotonin, 
and TXA2. Moreover, thrombin is a potent platelet activator56, which is one example 
of the interplay between the so-called primary and secondary hemostasis. Another 
example is that activated platelets expose phosphatidylserine (PS) on their 
phospholipid membrane surface, which facilitates propagation and enhancement of 
coagulation reactions66. The adhesion of platelets to the site of injury relies in part 
on receptor-mediated interaction of platelets with collagen directly. However, vWF, 
circulating in blood plasma, and additionally released from Weibel-Palade bodies of 
damaged endothelial cells and α-granules of activated platelets play an essential role 
in both platelet adhesion and platelet aggregation based on its ability to bind to 
subendothelial matrix proteins and cell membranes as well as to receptors on 
activated platelets56. Apart from forming a plug and supporting the coagulation 
cascade, activated platelets are capable of recruiting leukocytes, e.g. neutrophils, 
whose αMβ2 and P-selectin glycoprotein-1 (PSGL-1) interact with the platelets' 
GPIbα and P-selectin receptors, respectively49, while also monocytes, dendritic cells, 
and lymphocytes can be recruited by vessel wall adherent platelets67. 
Antiplatelet therapy 
Drugs that target the activation and aggregation of platelets can be used in the 
prevention and treatment of some types of thrombosis. Aspirin is a cyclooxygenase 
inhibitor and thus obstructs the formation of TXA2. P2Y12 receptor antagonists and 
glycoprotein IIb/IIIa inhibitors are other important antiplatelet drugs43,68. 
Fibrin clot formation 
The term ‘coagulation cascade’ refers to the similarity of the common model for 
coagulation, which was launched in 196469,70, with a waterfall or a cascade. It 
comprises a sequence of coagulation factors in the form of proenzymes, getting 
converted to their active enzyme forms by the ‘upstream’ activated coagulation 
factor56. This chain reaction can be activated by two different pathways, termed the 
intrinsic and the extrinsic pathway, respectively, both of them resulting in activation 
of coagulation factor X (FX) and thus of the final common pathway, eventually 
leading to fibrin formation71. All the components needed for initiation of the intrinsic 
pathway are present in the blood, while initiation of the extrinsic pathway is 
dependent on an external factor, namely TF56, although as mentioned, it is now 
known that some amount of TF actually circulates in the blood. 
The extrinsic pathway, which is the more important in order to trigger the 
hemostatic response in vivo38,56, is initiated with the aforementioned TF:FVIIa 
complex, also known as the extrinsic tenase complex, which cleaves FX to FXa. 
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Furthermore, the TF:FVIIa complex is capable of a converting FIX into FIXa71. 
The intrinsic pathway is activated when coagulation factor XII (FXII) in the blood is 
exposed to a hydrophilic surface to which it can bind, leading to accumulation and 
autoactivation of FXII, which can happen in vitro or in vivo56,71. Activated FXII (FXIIa) 
cleaves prekallikrein into kallikrein and coagulation factor XI (FXI) into activated FXI 
(FXIa). FXIa in turn activates coagulation factor IX (FIX) in a reaction that depends on 
the presence of ionized calcium, and next, activated FIX (FIXa) in concert with its 
cofactor, FVIIIa (activated coagulation factor VIII), forms the intrinsic tenase 
complex38,71. When assembled on a negatively charged phospholipid surface, such as 
the membrane of activated endothelial cells and platelets, the tenase complex 
converts FX to its activated form (FXa).  
The final common pathway begins with the activation of FX by either the intrinsic or 
the extrinsic pathway. FXa forms part of the so-called prothrombinase complex, 
which also includes activated coagulation factor V (FVa) and is dependent on calcium 
and a negatively charged phospholipid surface. The prothrombinase complex 
converts prothrombin to thrombin, and next, thrombin cleaves fibrinopeptides from 
fibrinogen, generating fibrin monomers which subsequently polymerize, forming the 
fibrin clot38. 
The fibrin clot helps stabilize the platelet plug, and also circulating erythrocytes and 
leukocytes become incorporated in the structure72. The fibrin clot is strengthened by 
the thrombin-mediated activation of coagulation factor XIII (FXIII) to its active form, 
FXIIIa, which induces covalent crosslinking between neighbouring fibrin polymers. 
Besides activation of FXIII and platelets, thrombin has several functions, including 
activation of FV, FVIII, FXI, thereby accelerating the production of thrombin itself56. 
Thus, a positive feedback loop leads to amplification and propagation of coagulation 
on the surface of activated platelets43. 
Anticoagulant therapy 
FII, FVII, FIX, and FX are vitamin K-dependent, meaning that their synthesis in the 
liver is dependent on sufficient amounts of active vitamin K. The so-called vitamin K 
antagonists (VKAs) which reduce the levels of active vitamin K are therefore effective 
inhibitors of the coagulation cascade and represent the classical type of oral 
anticoagulants. The more recently developed direct oral anticoagulants (DOACs) 
directly inhibit either FIIa or FXa73. Unfractionated and fractionated heparins 
represent another group of drugs that inhibit the coagulation cascade, which they 
do by markedly increasing the anticoagulant potency of one of the natural 
coagulation inhibitors, namely antithrombin68. 
Natural coagulation inhibition 
As indicated in the description of endothelial cells and leukocytes, several 
mechanisms that inhibit platelet function and the coagulation cascade exist. This 
helps maintain proper hemostasis, which represents a balance between 
procoagulant systems and anticoagulant systems43. While thrombin is a key player 
in the positive feedback loop that enhances the hemostatic process, it also plays an 
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important role in the downregulation of the coagulation process, as it binds to TM  
and activates an enzyme called protein C, which is bound to the membrane protein 
called EPCR. Activated protein C forms a complex with its cofactor, protein S, and 
this complex inactivates FVa and FVIIIa and thereby inhibits the intrinsic tenase 
complex and the prothrombinase complex56. Antithrombin downregulates the 
clotting cascade by inhibiting thrombin and FXa and to a lesser exent by inactivating 
FIXa, FXIa, and XIIa74. TFPI is another coagulation protein inhibitor. TFPI is partially 
dependent on protein S and can inhibit FXa and act to inactivate the TF/FVIIa 
complex. Yet other modulators of coagulation exist in the fairly complex hemostatic 
system in which some agents have up- as well as downregulating effects on 
coagulation56. 
Fibrinolysis 
The fibrinolytic system is also an important element in the hemostatic balance as it 
provides for dissolution of blood clots formed during wound healing. The enzyme 
named plasmin is essential in fibrinolysis. The proenzyme, plasminogen, binds to the 
surface of the fibrin clot or a cell surface and can be converted into plasmin by tissue 
plasminogen activator (tPA) or urokinase type plasminogen activator (uPA). Plasmin 
cleaves fibrin and thus dissolves the clot43 Plasmin may also modulate the formation 
of the primary hemostatic plug, since GPIIb/IIIa and GPIbα are also plasmin 
substrates, and, furthermore, it may have the capacity to inactivate FVIIIa72. 
Fibrinolysis is, like the coagulation cascade, regulated by a number of inhibitors, 
including PAI-1, plasminogen activator inhibitor-2 (PAI-2), α2-antiplasmin, and 
thrombin activated fibrinolysis inhibitor (TAFI)43,72. 
MECHANISMS OF THROMBOSIS 
A successful interplay between the above outlined excitatory and inhibitory 
influences on plug and clot formation keeps the hemostatic balance. Changes or 
abnormalities of the different components may tip that balance towards bleeding or 
thrombosis. 
According to the common perception of Virchow’s triad, the circumstances that on 
a general level predispose to thrombosis are abnormalities in the vessel wall, 
abnormalities in the blood flow, and abnormalities in the blood constituents75. 
Red and white thrombi 
Traditionally, thrombi have been divided into so-called ‘red thrombi’, which are rich 
in fibrin and erythrocytes, and ‘white thrombi’, which are rich in platelets75. The 
white thrombi primarily form in the arterial system, while the formation of red 
thrombi takes place in low pressure systems, including veins and the cardiac atria76. 
Important factors contributing to the development of arterial thrombi include 
endothelial dysfunction and damage related to atherosclerosis, inflammation, 
hypertension, turbulent blood flow at stenotic regions and platelet hyperactivity77. 
The occurrence of venous thromboembolism (VTE), which comprises deep venous 
thrombosis (DVT) and pulmonary embolism (PE), is believed to be contingent on a 
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combination of stasis and hypercoagulability more than endothelial damage78. Well-
established inherited risk factors for VTE include deficiency in one of the natural 
coagulation inhibitors protein C, protein S, or antithrombin and gain-of-function 
mutations in the FII or FV gene78,79. 
 
The classification of thrombi into predominantly platelet-mediated white thrombi 
developing in arteries and fibrin-rich red thrombi developing in veins is consistent 
with the prevailing pharmacological management of thrombosis. Antiplatelet 
agents, such as aspirin, glycoprotein IIb/IIIa inhibitors, and P2Y12 antagonists are the 
main therapeutics against arterial thrombi, while agents directed against the 
coagulation pathway such as VKAs and DOACs are mainly used against venous 
thrombi43. However, platelets do also play a role in the formation of venous thrombi, 
and antiplatelet drugs are to some extent capable of preventing venous thrombi80. 
Likewise, anticoagulant drugs are effective for prevention and treatment of some 
types of arterial thrombi, e.g. coronary artery disease and arterial thromboembolism 
related to AF77,80. A clear-cut distinction between red and white thrombi has also 
been challenged by the suggestion of epidemiological associations between venous 
thromboembolism and atherothrombosis which may not least be due to the fact that 
the two disease entities have some risk factors in common, such as age, obesity, 
cigarette smoking, and metabolic syndrome81. 
Thrombosis in atrial fibrillation 
Thromboembolism is considered the most important complication of AF32. AF 
increases the overall stroke risk about five-fold82 and is the most common factor 
contributing to stroke in the elderly32. Thrombogenesis in the left cardiac atrium (LA) 
in patients with AF is multifactorial and the mechanisms, while not fully understood, 
involve all three elements of Virchow’s triad83. 
Stasis in the left atrium and the left atrial appendage 
As mentioned in the section on AF, the fibrillating atria do not contract properly. The 
faulty contractile function of the left atrium (LA), along with resulting LA 
enlargement, leads to stasis of blood in the left atrium, which is regarded as an 
important factor but not the only explanation of the formation of thrombi in the LA83. 
The left and the right cardiac atrium each have an extension in the form of a muscular 
pouch termed the left (LAA) and right atrial appendage (RAA), respectively. The LAA 
is a long, tubular, hooked structure into which there is a narrow entrance from the 
main part of the left atrium84. While the LAA is believed to have a hemodynamic 
function by acting as a decompression chamber in periods of high left atrial pressure 
due to its profound distensibility84, it is also the major site of intra-atrial thrombus 
formation in patients with atrial fibrillation as well as in patients with sinus rhythm83. 
In patients with AF the dimensions of the LAA change83. By use of transesophageal 
echocardiography, AF has been shown to reduce blood flow velocity and induce an 
abnormal flow pattern in the LAA85, and atrial thrombus formation has been 
correlated with reduced LAA flow velocities86.  
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Changes in blood composition 
Potential associations between AF and blood plasma markers of platelet activation, 
coagulation activation, fibrinolysis, inflammation, and endothelial function have 
been investigated in various studies. A meta-analysis reported on elevated levels of 
the coagulation activation markers D-Dimer, thrombin-antithrombin complex (TAT), 
prothrombin fragment 1 and 2 (F1+2), fibrinogen, and antithrombin-III (AT-III) in AF 
patients87. In the same study significantly higher levels of the platelet activation 
markers platelet factor-4, β-thromboglobulin, and P-selectin were described. vWF, 
which is a well-established marker of endothelial dysfunction and damage83, was also 
elevated in AF patients87. In some studies the composition of blood collected from 
the left atrial lumen has been investigated. However, these studies have mainly 
focused on patients with mitral stenosis88-95. In one of the studies91, it was examined 
if significant differences between intra-atrial and peripheral blood thrombogenicity 
indices, including fibrinogen and D-dimer, markers of platelet activation (P-selectin 
and β-tromboglobulin) and markers of endothelial dysfunction (TM and vWF), could 
be detected in patients with AF secondary to mitral stenosis. No significant 
differences were found and the conclusion of the study was that blood samples 
collected from a peripheral vein reflect intra-atrial indices of coagulability, platelet 
activation and endothelial dysfunction91. This conclusion, however, contrasts the 
findings of another study indicating elevations in intra-atrial levels of indices of 
coagulation activity, platelet activation, fibrinolysis, and endothelial dysfunction 
compared to peripheral venous levels94. These differences between intra-atrial and 
peripheral venous levels tended to be more distinct in patients with concurrent AF, 
which may be a result of limited spillover from the left atrium to the systemic 
circulation94. In one study blood was isolated directly from the atrial appendages96. 
This study indicated that markers of an intra-cardiac inflammatory state and markers 
of an extracellular matrix remodelling process in patients undergoing coronary artery 
bypass grafting may predict the development of post-operative AF. The intra-cardiac 
inflammatory state was reflected by increased peripheral hs-CRP-levels. 
As mentioned, inflammation and hemostasis are highly interrelated. Peripheral 
venous C-reactive protein (CRP) and interleukin-6 (IL-6) are plasma indices of 
inflammation and have been demonstrated to be elevated in AF patients97. CRP as 
well as IL-6 can stimulate in vitro TF expression in monocytes83. The relation between 
inflammation, AF and thrombosis is complex and a subject that is not exhausted. 
Since inflammation appears to be able to trigger AF and AF appears to be able to 
establish and maintain an inflammatory environment, it is a current matter of debate 
to which degree AF is both a cause and consequence of inflammation98. 
Furthermore, the development of AF-related thromboembolism has been associated 
with inflammatory activity99. 
 
While hemostatic, thrombotic, and inflammatory markers have thus been associated 
with AF, the mechanism of this association has not been established. It is well-known 
that AF is not seldom complicated by other cardiovascular diseases, and whether the 
increased levels of the hemostatic and thrombotic markers are actually a 
consequence of AF itself or instead markers of coexisting cardiovascular risk factors 
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is unsettled87. However, although controversial, it has been suggested that the 
increase in plasma vWF levels in AF patients is independent of structural heart 
disease and that vWF is a cause rather than a consequence of thrombus turnover in 
AF100. Another marker of endothelial dysfunction, namely reduced concentrations of 
NO, has been demonstrated in AF patients and suggested to play a role in their 
increased risk of thrombosis101. Interestingly, increased peripheral venous plasma 
levels of TF have also been demonstrated in AF patients102. The TF levels correlated 
significantly with plasma levels of VEGF which is a potent stimulator of synthesis and 
expression of TF in endothelial cells83, and the increased levels of these two proteins 
may be related to endothelial damage or dysfunction102. Hypoxia is known to 
upregulate VEGF, and it has been suggested that AF may cause tissue hypoxia102. 
Changes in the atrial wall 
In patients with chronic AF, the prevalence of LAA endocardial thickening with 
fibrous and elastic tissue has been shown to be significantly higher than in patients 
with sinus rhythm103. Fibrous thickening of the atrial endocardium has been 
associated with a so-called “rough endocardium” with a wrinkled appearance, and 
areas of endothelial denudation and thrombotic aggregations have been 
demonstrated to be significantly more frequent in patients with AF104. An 
immunohistochemistry study demonstrated increased endothelial expression of TF 
and vWF in LAAs collected from patients with nonvalvular AF and recent 
thromboembolism when compared with LAAs collected as autopsy specimens from 
patients without AF who died of noncardiac events105. The protein overexpression 
was particularly marked in tissues containing inflammatory cells, especially T cells, 
and in areas that also contained denuded matrix of the endocardium105. Another 
immunostaining study demonstrated increased vWF in the the LAA of patients with 
mitral valvular disease irrespective of whether AF was present or not106, and 
Goldsmith et al. noted that mitral valve disease per se causes endocardial damage 
and potentially thrombogenic changes in the LAA107. 
Animal models of AF have indicated reduced expression of NO in the LA as a 
consequence of the loss of atrial contraction. Regarding the deeper layers of the 
atrial wall, it has also been suggested that AF could be associated with chamber 
specific changes in myocardial collagen content and amounts of proteins involved in 
degradation of extracellular matrix and that that disruption of the extracellular 
matrix may be linked to thrombogenesis by introducing fibrosis and infiltration of 
the endocardium83. 
Thrombosis prophylaxis in atrial fibrillation 
As mentioned, the cardiac atria represent low pressure environments as do veins, 
which, according to the distinction between red and white thrombi, is consistent 
with the fact that anticoagulant therapy more effectively than antiplatelet therapy 
lowers the risk of AF-related thrombosis77. An immunohistological study on the 
composition of thrombi present in the atrial appendage and thrombi having 
embolized to an artery in patients with AF indicated that fibrin and amorphous debris 
are the main components of atrial thrombi in situ, while in embolized thrombi the 
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main components are fibrin and platelets108. 
The current guidelines from the European Society of Cardiology (ESC) indicate that 
oral anticoagulant therapy (OAC) can prevent the majority of strokes in AF and that, 
except for patients at very low stroke risk, OAC should be used in most patients with 
AF, although bleeding risk related to anticoagulant therapy must also be considered 
when planning the prophylactic strategy for a given patient8. The recommended 
basis for decision is the so-called CHA2DS2-VASc score which takes into account 
important risk factors of stroke in AF patients, namely congestive heart failure, 
hypertension, age, diabetes mellitus, vascular disease, and sex8. Plasma biomarkers 
are not part of this risk score system, although vWF has been suggested to have a 
prognostic value in AF, and, in AF patients receiving anticoagulation therapy, D-dimer 
has been shown to predict thromboembolic events100. 
Various bleeding risk scores exist, including the so-called HAS-BLED score that takes 
into account hypertension, abnormal liver/renal function, stroke, bleeding history or 
predisposition, labile INR, age (elderly), and concomitant use of drugs predisposing 
to bleeding, such as platelet inhibitors or nonsteroidal anti-inflammatory drugs8. 
Recently discovered potentially prothrombotic factors 
While risk of thrombosis in cardiovascular disease is predominantly evaluated by 
clinical factors, there is a continuous pursuit of elucidation of the complex 
mechanisms of thrombosis and of biochemical and cellular parameters that will 
allow for more refined risk assessment and more precisely targeted approaches to 
thrombosis prevention109. 
Postprandial changes in blood composition 
Postprandial elevations of triglyceride-rich lipoproteins (TRLs), which include 
chylomicrons and very low density lipoproteins (VLDLs) are related to the risk of 
atherothrombotic disease, and it has been debated to which extent postprandial 
activation of the coagulation system is a contributing factor110,111. Increased plasma 
levels of FVIIa, TAT, and F1+2, and EVs in the postprandial state have been 
reported110. 
Blood-borne tissue factor 
Motton et al. hypothesized that postprandial lipemia is associated with an increase 
in the levels of blood-borne TF and performed a study that did indeed indicated 
elevated postprandial levels of circulating TF111. The authors stated that the blood-
borne TF which they detected using an enzyme-linked immunosorbent assay (ELISA) 
represented both EV-associated TF and soluble asTF. The increased levels of 
circulating TF were not accompanied by significant changes in TF activity111. 
In the aforementioned immunohistological study on the composition of AF-related 
thrombi, TF was colocalized to areas that were rich in platelets and granulocytes, and 
it was suggested that circulating TF may play a part in thrombus initiation as well as 
propagation108. 
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Procoagulant extracellular vesicles 
EVs, which appear to account for a greater or lesser part of total amounts of 
circulating TF, have been the pivot for much of the experimental work performed in 
this PhD project and will be further introduced in the next and final section of the 
background chapter. 
 
Along with EVs, NETs have been mentioned as more recently discovered players in 
in thrombotic processes and potential targets for antithrombotic therapy48, and in 
study 4 of this project, we took interest in their potential contribution to thrombosis 
in AF. An introduction of NETs will close the present section. 
Neutrophil extracellular traps 
The discovery of NET release as a mechanism used by neutrophils for microbial killing 
was made in 2004112. NETs are web-like structures consisting of chromatin filaments 
and proteins such as histones and serine proteases released by activated neutrophils 
as a response to microbial and inflammatory stimuli113. Activation of neutrophils can 
occur via stimulating agents such as cytokines, growth factors and the complement 
system114. 
It is well-described that neutrophils are an essential part of the innate immune 
system. They are quickly recruited to pathogen-infected tissues but also to sites with 
sterile injury, extravasating from the blood and entering affected tissues where they 
phagocytically engulf microorganisms and cellular debris. The release of NETs, so-
called ‘NETosis’ which can take place intravascularly, represents another protective 
mechanism performed by neutrophils. The chromatin structures which, when 
released, are markedly larger than the neutrophils themselves, are capable of 
immobilizing pathogens, restraining them in an area with a high concentration of 
antimicrobial proteins such as neutrophil elastase and myeloperoxidase released 
from the neutrophils’ intracellular granules115,116. NETs represent one of the many 
links between inflammation and coagulation. NETs may play a role in so-called 
immunothrombosis which represents a form of protective thrombosis taking place 
in microvessels, limiting the spreading and survival of circulating microbes. However, 
apart from the protective functions, NETosis can also promote harmful thrombosis. 
In animal models NETs have been shown to enhance in vivo venous thrombosis, and 
extracellular nucleosomes, which constitute the main part of NETs, have been shown 
to promote arterial thrombosis116. 
Different mechanisms link NETosis and coagulation. Neutrophil elastase can cleave 
and inactivate TFPI and thus enhance procoagulant activity which leads to platelet 
activation, and activated platelets can in turn enhance NET formation117. Neutrophils 
and platelets both release EVs that may express TF and may be trapped by NETs116. 
Furthermore, NETs can trigger the intrinsic coagulation pathway via FXII activation 
and may inhibit tPA-mediated fibrinolysis116. 
While NETosis was initially regarded as a process solely occurring as part of a cell-
death program during which the NET-releasing neutrophil would perish, it has more 
recently been discovered that also another form of NETosis, termed vital NETosis, 
which takes place more rapidly and which allows the neutrophil to survive and 
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maintain its phagocytic function, occurs113,114. While in suicidal NETosis the 
chromatin and proteins are released from the neutrophil via disruption of the plasma 
membrane, the release mechanism in vital NETosis involves transport of the NETs to 
the plasma membrane by intracellular vesicles whose contents are then released 
into the extracellular space114. 
EXTRACELLULAR VESICLES 
EARLY EVIDENCE  
“When clotting occurs, coagulant particulate material is released from platelets, 
considerably in excess of what is required for thrombin generation and it can be 
detected in serum. Its presence accounts for the platelet-like activity of serum.” 
The quote is from the scientific paper “The Nature and Significance of Platelet 
Products in Human Plasma” published by Peter Wolf in 1967. Wolf described this 
particulate material, which he termed “platelet dust”, as sedimentable by high-
speed centrifugation, visualizable by electron microscopy, and rich in lipid 
content118. The characterization of platelet dust is regarded as a milestone in the 
field of EVs42,119,120. When the initial discovery of EVs is discussed, Wolf’s work is 
often mentioned in connection with another paper published two decades earlier, 
namely “Biological Significance of the Thromboplastic Protein of Blood” by Erwin 
Chargaff and Randolph West121. Chargaff and West demonstrated that after a 150 
minute high-speed centrifugation of blood at 31,000 x g the supernatant plasma lost 
coagulation capacity as indicated by increased clotting time, while 
“The particulate fraction sedimented at 31,000g probably includes, in addition to the 
thromboplastic agent, a variety of minute breakdown products of the blood 
corpuscles.” 
Erwin Chargaff and Randolph West, 1946121.     
As it appears from these early descriptions of a sedimentable blood plasma fraction 
containing particles released from cellular elements and exhibiting coagulant 
capacity, the cradle of EV research was anchored to an interest in the mechanisms 
of blood coagulation and, in a chronological perspective, it rocked alongside the 
studies that formed the basis for the coagulation cascade model. 
Since then, the field of EVs has evolved markedly and has attracted growing interest 
from researchers in hemostasis and thrombosis but also in several other branches of 
medical and non-medical science. 
CURRENT STATE OF THE ART 
In recent decades an increasing amount of evidence has indicated that several types 
of cells release vesicles of varying size into various body fluids by different 
mechanisms and that these vesicles are involved in numerous physiological and 
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pathological processes122. Apart from blood, EVs have been isolated from 
cerebrospinal fluid, amniotic fluid, milk, saliva, nasal secretions, ascites, pleural 
effusions, bronchoalveolar lavage, bile, synovial fluid, ocular effluent, aqueous 
humor, semen, and urine123. The cellular origin, molecular content, functional 
properties, and amounts of EVs depend on the type of body fluid and have been 
demonstrated to be associated with bodily conditions and diseases such as 
inflammation, cardiovascular disease, and cancer124. EVs can contain many of the 
same membranous and cytosolic elements as their parent cells and exert their 
biological effects in different ways. A key feature of EVs seems to be their ability to 
transfer information from one cell to another. In this way they represent a cell-to-
cell signaling method which supplements the more classically described juxtacrine, 
autocrine, and endocrine signaling forms that are continuously brought into play in 
humans and other multicellular organisms. The EV-associated signals can be 
transmitted by molecules such as proteins, carbohydrates, and lipids42. Studies from 
the past ten years have shown that the ‘cargo’ of EVs can also include some 
deoxyribonucleic acids (DNAs) and several subtypes of ribonucleic acids (RNAs), 
which can be transferred via the EVs to recipient cells125. The transport of molecules 
by EVs does not only function as a means of intercellular communication but also as 
a way to eliminate molecules, e.g. amyloid proteins and modified RNAs, from cells122. 
  
Along with the awareness of their existence and potential biological significance, an 
interest in the potential use of EV measurements for diagnostic and prognostic 
purposes has developed. Also, EVs have been mentioned as potential future 
therapeutic targets48,126,127. However, EVs are a very heterogenous group of analytes, 
and it is challenging to isolate, quantify, and characterize them in order to distinguish 
the different types of EVs from each other and from similarly sized components in 
their environment. 
Nomenclature and mechanisms of release 
The complexity and heterogeneity of these cell-derived phospholipid-bilayer 
membrane-enclosed particles, that can collectively be termed EVs, reflect in 
problematics of the nomenclature in the field. In some contexts, vesicles have been 
given names such as “prostasomes” or “synaptic vesicles” based on the cells or tissue 
of their origin119, in other cases based on their biological function, e.g. “tolerasomes” 
for vesicles that induce immunological tolerance128. Broader terms have been used 
to designate the main types of EVs, based on the mechanisms of their biogenesis and 
release. In general terms, cells have been decribed to release EVs under conditions 
that imply ‘cell stress’, i.e. upon cell activation or during apoptosis124,129. In recent 
reviews on the topic, two main types of EVs released from vital cells are mentioned, 
namely microvesicles (MVs) and exosomes42,122,125,130, while apoptotic bodies 
released from cells undergoing apoptosis can be regarded as a third main type of 
EVs42,124,125. These three types of EVs will be introduced in more detail after a brief 
description of factors that can trigger EV release. 
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The range of stimuli that may potentially cause cell stress or activation leading to EV 
release is not limpid but several pathways appear to exist. In vitro studies have 
indicated that release of EVs from the plasma membrane is induced by stimuli that 
give rise to an increase in intracellular calcium concentration, and treatment with 
calcium ionophores, which allows divalent cations to cross cell membranes, has been 
shown to increase MV and exosome release from leukocytes131. Bacterial 
lipopolysaccharide (LPS) has also been demonstrated to induce EV release from 
dendritic cells132 and endothelial cells133. Endothelial cells also form EVs in vitro after 
stimulation with various cytokines and reactive oxygen species133. The effect of food 
intake on the EV population in the blood is not well known123. However, consumption 
of a high-fat meal has been shown to increase levels of endothelial EVs, and although 
the mechanism is not clear, endothelial EVs were suggested to be markers of 
endothelial dysfunction induced by postprandial hypertriglyceridemia134. Platelet-
derived MVs are released as a response to shear stress and agitation as well as 
stimulation with collagen, thrombin, or ADP. Platelet activation leading to MV 
release can take place via their thrombin receptors, GPVI collagen receptors, or the 
P2X purinoreceptor 7, which is a receptor for ATP. However, a study has also 
demonstrated increased concentrations of platelet-derived EVs in the postprandial 
state, interpreted as an indication of hypertriglyceridemia-induced platelet 
activation135.  
Activation of B cells, T cells, mast cell, and reticulocytes via their surface receptors 
and subsequent EV release from these cells has also been described133. 
Furthermore, constitutive release of EVs from cells such as natural killer cells42, T 
cells, and B cells131 has been described. Moreover, tumor cells have been reported 
to constitutively secrete MVs, exosomes, and apoptotic bodies133. EV secretion may 
also be affected by gene polymorphisms133. 
Exosomes  
Exosomes originate in the endocytic system of the cell and are subsequently secreted 
through the plasma membrane by a mechanism initially discovered in electron 
microscopy (EM)-based studies in the 1980s136. 
Endosomes are membrane-enclosed intracellular compartments formed during a 
cell's internalization of extracellular components in a process that involves 
invagination and fission of the plasma membrane. Endosomes contain fluid, solutes, 
macromolecules, particles, and plasma membrane components137. 
Inward budding of the membrane of the early endosome can take place and lead to 
the formation of intraluminal vesicles (ILVs) which accumulate in the endosome, 
resulting in the transformation of the endosome into a so-called multivesicular body 
(MVB). ILV formation can follow different pathways, the best characterized being the 
endosomal sorting complex required for transport (ESCRT) pathway, which involves 
four protein complexes  termed ESCRT-0, -I, -II, and –III and some accessory proteins, 
each playing their part in binding, sorting, and clustering receptors and other 
proteins at the endosomal membrane and incorporating them in ILVs. A 
transmembrane protein superfamily termed tetraspanins is involved in the initial 
clustering of this ILV formation machinery, which takes place in tetraspanin-enriched 
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microdomains (TEMs) of the endosomal membrane. Another ILV formation pathway 
involves lipid rafts, which are specialized membrane microdomains with a lipid 
composition that differs from other regions of the endosomal membrane. Thus, 
sphingomyelin is clustered in lipid rafts and converted into ceramide, which in turn 
induces inward membrane budding so ILVs are formed122,125,138. 
In the majority of cells, most MVBs fuse with lysosomes that degrade their cargo, but 
some MVBs instead travel to the plasma membrane and fuse with it, releasing their 
content, to the extracellular compartment. After release, the former ILVs are termed 
exosomes. The transport of ILVs to the membrane and the release of exosomes 
depend on interactions between the plasma membrane and the cytoskeleton as well 
as local enzymatic degradation, and activation of mechanisms that facilitate 
membrane fusion. The tetraspanin protein superfamily is involved in the secretion 
as well as the biogenesis of exosomes125. Studies on the composition of exosomes 
indicate that they contain specific subsets of proteins, RNAs and lipids rather than a 
random selection of these molecules from their parent cell. This substantiates the 
perception of the existence of mechanisms for sorting specific molecules into ILVs 
prior to their release as exosomes although the composition varies considerably 
between different exosomes131. In relation to the description of platelets in the 
previous section, it can be mentioned that the α-granules in platelets also represent 
a type of matured MVBs that have been provided with endogenous cargo such as 
vWF from the Golgi apparatus of megakaryocytes139. 
In EM studies, the diameters of ILVs have been estimated to range between 30 and 
100 nm131, and the maximal diameter of exosomes were earlier described as being 
around 100 nm119,136,138, while later reviews suggest a maximal exosome diameter of 
150 nm122,125,140, although at the ISEV meeting in 2015 diameters up to 250 nm were 
reported141.  
Microvesicles 
MV biogenesis takes place at the periphery of the cell by direct outward budding 
from the plasma membrane in processes that on a general level mainly rely on 
membrane constituents, cytoskeletal functions, and proteins recruited for cutting 
the plasma membrane. On a more detailed level, different mechanisms have been 
described, and the specific mechanisms that come into play for MV biogenesis may 
vary between cell types and function125. 
Consensus exists that a central element in MV formation is disruption of the 
asymmetry of lipids in the plasma membrane. In the normal plasma membrane some 
phospholipid subtypes, including PS and phosphatidylethanolamine, are 
predominantly situated in the inner leaflet of the lipid bilayer, while 
phosphatidylcholine and sphingomyelin are enriched in the outer leaflet. This 
membrane asymmetry is influenced by lipid translocases, which exchange lipids 
between the internal and external leaflet. Flippase is an inward directed lipid 
translocase that serves to maintain membrane asymmetry by flipping divagated PS 
and phosphatidylethanolamine back in place in the inner leaflet, while floppase is an 
outward directed lipid translocase, and scramblase is a bidirectional translocase that 
promotes unspecific redistribution of lipids between the leaflets142. Flippase and 
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floppase use ATP when they translocate lipids, while scramblase is ATP-
independent143. Mechanisms that lead to local increase in intracellular calcium 
concentration interrupt membrane asymmetry, since calcium stimulates floppase 
and scramblase activity while flippase activity is attenuated by elevated calcium 
concentration. The redistribution of PS to the external membrane leaflet is 
particularly important in this connection, since the thereby occurring structural 
imbalance makes the lipid bilayer bulge in the direction of the outer leaflet and 
promotes MV release. The PS translocation may potentially be sufficient for inducing 
MV release, but moreover, increased cytosolic calcium concentration activates 
intracellular proteins such as calpain and Rho kinase, which are responsible for 
cleaving and changing the membrane cytoskeleton, which leads to cellular 
contraction and membrane blebbing120,125.  
As mentioned, different mechanisms for MV release may be brought into play in 
different situations. Thus, changes in ceramide content in the external leaflet of the 
plasma membrane induced by acid sphingomyelase can also promote membrane 
curvature and MV release, and more recently, it was suggested that components of 
the ESCRT system that was mentioned in the description of exosome biogenesis may 
play an important role in MV biogenesis at the plasma membrane as well122,125. MVs 
contain the same overall types of cargo as exosomes, and PS is not restricted to MVs 
but also exists on exosomes125.  
As for the size of MVs, different ranges such as 200-500 nm122, 100-1000 nm136, 150-
1000 nm131, and 50-1000 nm144  have been proposed, so looked upon as a group they 
have a broader size range and are generally larger than exosomes. 
As mentioned, the nomenclature in the field has not been stringent, and terms as 
ectosome, microparticle, and shedding vesicle have been and are still used more or 
less synonymously with the term MV in the literature42,125,131. In this context, the 
term MVs is used for EVs released by direct budding of the plasma membrane of vital 
cells, which appears to be the preferred term in the ISEV community42. 
Apoptotic bodies 
Apoptosis is programmed cell death that occurs as part of tissue homeostasis. 
Apoptosis can be induced via an extrinsic pathway that involves the interaction of a 
transmembrane receptor with a ligand, e.g. TNF-α, or via an intrinsic pathway as a 
response to lack of certain growth factors, hormones, or cytokines or the presence 
of stimuli such as toxins, hypoxia, and hyperthermia. Cells undergoing apoptosis 
form blebs at the plasma membrane in a process that involves caspase dependent 
degradation of the cytoskeleton, loss of membrane interaction with the cytoskeleton 
and externalization of PS to the outer leaflet of the phospholipid bilayer. Membrane 
blebbing leads to budding and release of apoptotic bodies containing cytoplasm, 
organelles, and in some cases a nuclear fragment145. Apoptotic bodies, also termed 
apoptotic vesicles124, may contain relatively more genomic DNA than other types of 
EVs122. While apoptotic body release involves some of the same mechanisms that 
are brought into play in MV release, during apoptosis the PS redistribution mainly 
relies on a calcium independent caspase. Although the process of packing cellular 
debris into apoptotic bodies has not been detailedly characterized, indications exist 
 
34 
that it involves a highly regulated process in which particular cellular contents are 
incorporated in these EVs, which are released for subsequent phagocytosis, as 
phagocytes will perceive their PS exposure as an “eat me”-signal. In this way clearing 
of potentially harmful, inflammation inducing substances in membrane-enclosed 
entities prevents their leakage into tissues125.  
Interestingly, although MVs and exosomes also expose PS in their outer membrane 
leaflet they can have longer life-times and intercellular signaling functions. It has 
been suggested that MVs may not possess certain accompanying “find me” signals 
necessary for attraction of phagocytes, that PS on MVs may be less abundant and 
presented differently, and that a surface coating provided by proteins recruited 
during MV budding may prevent interactions with PS125.  
The size range of apoptotic bodies has been reported to range from diameters of 
1000 nm to diameters of 5000 nm119, although some may be down to 500 nm146, but 
their size distribution has not been systematically investigated125. 
Fate and function 
While apoptotic bodies are destined for phagocytosis and thus primarily represent a 
stage in the process of cell dismantling and biomolecule recycling125, it has been 
suggested that inappropriate clearance of apoptotic bodies play an important role in 
systemic autoimmune disease119. 
MVs and exosomes, on the other hand, are regarded as potential mediators of 
advanced communication between cells and contributors to processes such as 
coagulation, angiogenesis, inflammation, and modulation of immune responses124. 
Thus, they appear to have destinies beyond allowing cells to dispose of waste 
material, and blood content of EVs can be regarded as a dynamic balance between 
their release and clearance147. Clearance of EVs from the circulation has been 
suggested to take place via interactions with recipient cells, uptake in the 
reticuloendothelial system, or excretion via the liver or kidneys148.  
The phospholipid bilayer enclosing the EVs enables them to carry and protect their 
internal cargo and travel to target cells on which the EVs can exert their effect via 
ligand-receptor-based interactions or direct delivery of cargo into the cytosol of the 
recipient cell after EV fusion with the plasma membrane122,140. The interest in and 
research on EVs as carriers of functional molecules between cells did not least gather 
speed after the discovery in 2007 of exosomes containing messenger RNAs and 
microRNAs and the successful in vitro transfer of functional translatable mRNA via 
mast cell-derived exosomes from donor cells into recipient mast cells149. However, 
although in a review article from 2017, Maas et al. mentioned that in vivo cells 
continuously exchange EVs over short and long distances, potentially even 
occasionally crossing the blood-brain barrier, in the same paper the field is described 
as still young and holding several ‘black holes’, one of them being the true 
spatiotemporal fate of EVs in vivo122. In another recent review Kalra et al. stated that 
whether packaging of cargo into exosomes, MVs, and apoptotic bodies is actually a 
selective or random process is largely unknown, thereby urging some caution when 
interpreting the ostensible cell-communication-related functions of EVs125. 
However, the omnipresence of EVs in biological fluids and more or less specific 
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changes in their molecular content depending on the type and pathophysiological 
state of the parent cells, make them interesting as potential biomarkers. Changed 
levels of subtypes of EVs have been identified in wide range of disorders, including 
metabolic, hematologic, infectious, autoimmune, cardiovascular, and neurological 
diseases as well as in preeclampsia, and several cancers122,133. 
In the context of this PhD project, the potential role of EVs in hemostasis and 
thrombosis was of particular interest. The mechanisms by which EVs expectedly 
affect the coagulation system do not necessarily involve sophisticated transfer of 
internal EV cargo to recipient cells but instead appears to be based mainly on their 
membrane content. 
Extracellular vesicles in hemostasis and thrombosis 
As mentioned in the beginning of this section, the first evidence of the existence of 
EVs was related to their procoagulant properties. While the potential relation of EVs 
to many other medical fields has been investigated, their ability to enhance 
coagulation is still regarded as their most widely accepted physiological role and one 
of their best characterized features42,146. 
Early indications on the existence of blood-borne TF and its possible association to 
EVs was published by Giesen et al. in 1999, questioning the previously prevailing 
paradigm that TF under normal conditions is not present in blood but exclusively 
resides outside the vascular lumen150. The investigators observed that when pig 
aortic media and collagen-coated glass slides, none of which stained positive for TF 
in themselves, were perfused with native human blood, thrombi staining positive for 
TF formed on the glass slides as well as on the aortic media. Repeating this 
experiment with the addition of anti-human TF antibody resulted in markedly 
reduced thrombus formation. Immunoelectron microscopy of the thrombi, which 
consisted primarily of fibrin, revealed that TF predominantly colocalized to 
membrane-enclosed vesicles and that these vesicles were often clustered next to 
platelets. Furthermore, the presence of TF-containing monocytes and neutrophils in 
the blood was demonstrated. Based on their results, the authors suggested that 
arterial thrombus propagation involves deposition of blood-borne vesicle-associated 
TF on platelets in the developing thrombus, allowing for coagulation factors to be in 
close proximity to TF and the platelet surface at the same time150. 
Since then, several experimental studies on the potential role of EVs in thrombus 
initation and propagation have been performed, not least by a Boston-based 
research group, who established a method for in vivo brightfield microscopic imaging 
of thrombus formation151. The method involved labeling of cellular and protein 
components in the blood using fluorescent antibodies, thus allowing for studying the 
pattern of accumulation of these components in a growing thrombus after 
prompting its formation by inducing an endothelial injury in a cremaster muscle 
arteriole in a living mouse. Among the findings in this in vivo model was accumulation 
of TF, accumulation of platelets expressing P-selectin, and generation of fibrin at the 
site of endothelial injury. Advanced studies, which included investigations on P-
 
36 
selectin null mice and infusion of isolated monocyte-derived EVs, indicated that the 
accumulation of TF-bearing EVs is due to binding of P-selectin on activated platelets 
to PSGL-1 on the EV surface152. Leukocytes, another potential supplier of blood-
borne TF to the site of injury, were also incorporated in the developing thrombi. 
However, studies on the kinetics of accumulation of TF, EVs, and leukocytes in the 
thrombi suggested that TF originating from hemopoietic cells is provided via EVs in 
the initial phase of thrombus generation while leukocytes themselves accumulate 
minutes later153. 
 
As described in the section on the hemostatic system, the tenase and 
prothrombinase activity that leads to downstream fibrin generation, depend on the 
presence of a negatively charged phospholipid surface. Such a surface exists on 
activated platelets and endothelial cells, and in addition on EVs. Thus, the presence 
of PS molecules on the external leaflet of EVs, not least MVs on which PS is often 
abundant, is considered to enable these vesicles to facilitate the assembly of 
coagulation factors and thus promote coagulation126. Since MVs from platelets 
express receptors for both collagen and vWF, it has been stated that they can be 
viewed as smaller versions of activated platelets154, and an in vitro study has 
indicated that platelet-derived MVs actually display even considerably higher 
procoagulant activity than activated platelets155. Importantly, some EVs carry TF in 
their membrane, and it has been stated that MVs which expose TF and PS at the 
same time have the highest level of procoagulant activity154. While most of the 
evidence on TF-bearing EVs concerns MVs, studies on cancer-related EVs have 
indicated that exosomes can also carry TF156. 
The abundance, origin, and biological relevance of TF-exposing EVs in the blood in 
physiological and pathological contexts is not clear. While studies have indicated that 
platelets, or megakaryocytes, are the major source of PS-bearing MVs, monocytes 
have been stated to plausibly be the main source of TF-bearing MVs. TF-bearing MVs 
may under some conditions be released by other cell types, including neutrophils, 
endothelial cells, and platelets, although contradictory data exist on this topic154. An 
in vitro study by Aleman et al. indicated that while MVs from both leukocytes and 
platelets can contribute to clot propagation, the leukocyte-derived MVs were 
capable of also initiating the ‘extrinsic’ TF-dependent pathway. The platelet-derived 
MVs did not exhibit such TF activity, but nevertheless they accelerated thrombin 
generation and fibrin formation when mixed with the monocyte-derived ones61. 
Sabatier et al. demonstrated that endothelial cell-derived MVs can interact with 
monocyte-derived MVs in vitro and make them exhibit increased levels of TF antigen 
and TF mRNA as well as increased procoagulant activity157, while the direct 
contribution of endothelial EVs to blood-borne TF has been described as probably 
limited in the absence of stimulation but potentially important in case of drastic 
endothelial activation126.  
Hoffman et al. conducted an in vitro study in a mouse model, which suggested that 
blood-borne TF can contribute to thrombosis in some circumstances but probably 
not to normal hemostasis158. 
Some recent studies have suggested that MVs may also promote coagulation via 
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mechanisms that are independent of TF and the extrinsic pathway but instead 
involve FXI and FXII, although additional investigations are needed to gain thorough 
insight into this aspect146. At present, the major determinant of the coagulant 
capacity of EVs is believed to be the presence or absence of TF in their membrane42, 
while considerable procoagulant potiential is also ascribed to PS147. It should also be 
noted that MVs do not only exhibit procoagulant capacity but also have been 
demonstrated to possess the ability to downregulate coagulation by harboring of 
TFPI on their membrane, supporting protein C and protein S mediated regulation of 
coagulation, and assisting plasmin generation. These findings have given rise to the 
view that the complex role of MVs in coagulation represents a balance between pro- 
and anticoagulant properties and that their net effect in hemostasis and thrombosis 
is at any time determined by the current state of that balance146. 
The interplay between different cell types and the EVs released from them in relation 
to hemostasis and thrombosis appears complex and many-faceted, and many sorts 
of interactions such as fusions and exchanges between the membranes of EVs from 
monocytes, endothelial cells and platelets may take place in vivo and in vitro126. 
Furthermore, when aiming to obtain preparations of EVs with specific cellular origin 
some degree of contamination from other EV subtypes must be expected61, which 
represents one of the experimental challenges associated with this field. 
Whether or not signicant levels of functional blood-borne TF exists in the blood of 
healthy humans has been debated. Conflicting results have been reported, and 
some investigators have found very low levels of EV-associated TF activity154, which 
may be undetectable by some methods147. Different posttranslational 
modifications, such as glycosylation, of TF may result in different versions of TF 
exhibiting different levels of procoagulant activity, and it has been suggested that 
EV-associated TF may normally be present in a so-called ‘encrypted’ low-activity 
state, so that it will not activate the coagulation cascade untimely. The encrypted 
TF may then, when timely, be activated by different mechanisms, including 
potential conformational changes induced by PS154. 
In a review from 2016, Mooberry et al. noted that increased levels of circulating 
MVs have been reported in many inherently prothrombotic conditions, including 
malignancy, sepsis, thrombophilia, trauma, nephrotic syndrome, inflammatory 
bowel disease, systemic lupus erythematosus, pregnancy, and preeclampsia146. 
However, the authors stressed that in spite of these associations and in some cases 
also a correlation between MV concentrations and thrombotic events, a causal 
relationship between the increased MV levels and thrombotic events does not 
necessarily exist.  They also noted that only few prospective data exist and that 
these few data display conflicting results, possibly due to differences in applied 
methodologies. Anyhow, one prospective study found TF-positive MV levels 
measured by flow cytometry (FC) predictive of thrombosis in brain tumor patients 
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while another prospective but small study indicated that increasing levels of MV 
associated procoagulant activity over time correlated with subsequent 
development of thrombosis146. 
 
Extracellular vesicles in atrial fibrillation 
AF was not on the abovementioned list of prothrombotic conditions with increased 
circulating EV levels, and only a few studies have investigated EV levels in AF patients. 
In 2005, Chirinos et al. published a study on the potential effect of Digoxin use on 
peripheral venous plasma levels of markers of platelet and endothelial cell activation 
in patients with nonvalvular AF159. Increased levels of endothelial-derived MVs were 
detected in the Digoxin users, whereas no differences in platelet-derived MVs were 
found after adjustment for potential confounders. 
In a study published in 2007, Choudhury et al. hypothesized that the peripheral 
venous plasma concentration of platelet-derived EVs are elevated in nonvalvular AF 
patients as compared to healthy control subjects and furthermore as compared to a 
group of disease control subjects with a history of hypertension, coronary artery 
disease, diabetes, or stroke160. While data showed no difference in platelet-derived 
EV levels between AF patients and disease control subjects, both AF patients and 
disease control subjects displayed significantly higher levels than the healthy control 
subjects. AF did not prove to be an independent determinant of the concentration 
of neither platelet-derived EV levels nor soluble P-selectin, and the authors 
suggested that platelet activation in AF patients results from underlying 
cardiovascular disease. 
In another paper from 2007, Ederhy et al. found increased plasma levels of PS 
positive EVs in AF patients as compared to a control group without cardiovascular 
risk factors and compared to a control group with cardiovascular risk factors161. 
Regarding subgroups of EVs, i.e. endothelial-derived and platelet-derived EVs, the AF 
group and the control group with cardiovascular risk factors had similar levels, which 
were higher than in the group without cardiovascular risk factors. 
In 2009, Azzam et al. demonstrated that patients with valvular AF had higher plasma 
levels of platelet-derived EVs than healthy control subjects and that the severity of 
mitral stenosis correlated with levels of platelet-derived EVs162. 
In three of the abovementioned four studies on EV levels in AF patients, EV 
measurements were performed with FC, which reportedly is the most commonly 
used approach to EV analysis146. While FC can at high speed provide phenotypic 
information on EVs in a sample, the method also has considerable limitations as do 
other methods for EV detection, which along with preanalytical variables makes EV 
analysis on blood samples a challenging discipline. 
In the following, methods for EV detection are presented, and subsequently 
preanalytical and analytical issues, which can influence the results on EV 
measurement in blood, are introduced. Since the interference of lipoproteins on EV 
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measurements has been a focal point in this PhD project, space is given to an 
introduction of this group of particles. 
ANALYSIS 
Characterization of the EV population in a body fluid may include determination of 
variables such as the concentration, size distribution, morphology, biomolecular 
cargo, and membrane content. Depending on the features of interest, different 
methods can be applied, and combination of techniques may be relevant141. 
Microscopy techniques such as electron microscopy, as applied by Wolf118 and 
Giesen150 in their path-breaking work in the 1960s and 1990s, respectively, and 
atomic force microscopy can be used for studying size and morphology. Also, by use 
of antibody-based labeling, biochemical information can be obtained with these 
types of microscopy, while they are not suited for concentration determination163. 
Several other methodologies, including classical immunoassays, have been used for 
EV analysis and each has its advantages and disadvantages146. Western blotting can 
be used for determination of the proteins present in a pellet containing EVs but not 
for determination of EV concentration or size. ELISAs can capture some of the 
vesicles present but is not suited for discrimination between EV subtypes and also 
detects soluble antigens164. Specific clotting activity assays in which the measured 
clotting time is dependent on the amounts of procoagulant phospholipids (PPLs) 
have been used for estimation of levels of PPL-exposing EVs165. 
A number of optical, light scatter-based methods have been applied163, including FC, 
and nanoparticle tracking analysis (NTA), which will be briefly introduced in the 
following along with two other more recently launched methods for EV detection 
that have been explored and used in the studies done in this PhD project, namely 
tunable resistive pulse sensing (TRPS) and Extracellular vesicle Array (EV Array).   
Flow cytometry 
FC has been widely used for blood cell counting and characterization for decades and 
is currently also a common method for EV analysis which enables detection of tens 
of thousands of EVs per minute141. In a flow cytometer, particles are transported in 
a fluid stream through a detection device that detects the particles based on 
measurements of their impedance, fluorescence, and/or scattering of laser light 
applied in the flow cytometer. FC used for EV analysis relies on detection of light 
scattering and fluorescence, while impedance is measured in the more recently 
developed technology termed tunable resisistive pulse sensing (TRPS). 
When a particle passes through a laser beam, it scatters the light in different 
directions, depending on properties of the particle. The scattered light is measured 
by different detectors that can detect forward (FSC), and side scattered light (SSC). 
Theoretically, particles larger than the wavelength of the laser light will 
predominantly scatter light in a forward direction, and therefore FSC signal is 
associated with particle size163 and can be used to estimate the particle diameter. 
Particles smaller than the wavelength of the laser light will scatter relatively more 
light in a perpendicular direction163. When FC is a applied on a medium containing 
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cells, SSC is highly influenced by the internal composition of the cell, including 
granularity and nucleocytoplasmatic ratio166. When FC is used for analysis of EVs, 
which are much smaller than cells, SSC from the surface of the EVs tends to 
overwhelm SSC from the structures inside the vesicles163. However, the SSC signal 
can allow for a better resolution of small particles than when FSC is used alone166,167. 
Conventional FC does not allow for detection of particles smaller than around 300 
nm164,168 and since the majority of EVs are below this size it has been stated that FC 
is only capable of identifying the ‘tip of the iceberg’169,170 of EVs in a biological 
sample. Recently, new flow cytometers have been developed, allowing for flow 
cytometric detection of polystyrene particles as small as about 100 nm141 but the 
light scatter intensities of the smallest EVs may often be below background noise171. 
The sensitivity and specificity of FC can be further increased by fluorescent labeling 
of the EVs141. Labeling EVs can help distinguish EVs from other particles present in 
the studied medium, and cell type specific antigens in the EV membrane can serve 
as markers of cellular origin167.  
While the principles of FC are well suited to detect, count, and characterize EVs, 
further instrument improvements are needed for full EV phenotyping in biofluids171. 
At meetings in ISEV and the International Society on Advancement of Cytometry 
(ISAC) it was agreed that other measurement techniques such as NTA and TRPS 
should be used alongside FC141. 
Nanoparticle tracking analysis 
Like FC, NTA is based on detection of scattered light but the principle of the method 
is very different. In NTA, which was introduced in 2006, the suspension of interest is 
illuminated by a laser beam via a glass prism. Particles in the suspension scatter light, 
and a microscope with a video camera collects the scattered light in the field of view, 
thus visualizing and recording each particle present in the field of view. The recorded 
video is analyzed by NTA software, which provides for identification and frame-to-
frame tracking of each particle. This enables determination of the velocity of each 
particle’s Brownian motion, which can then be used to calculate its hydrodynamic 
diameter by applying the Stokes-Einstein equation when the temperature, sampling 
time and sample viscosity is known164,172. Also the particle concentration is estimated 
by the software, and data are presented as a histogram of particle diameter versus 
particle concentration. NTA enables detection of particles with diameters down to 
10-35 nm173-175. Thus, NTA allows for the measurement of particles considerably 
smaller than those detected by FC. However, NTA does not provide identification of 
EV phenotyping or distinction between EVs and other particle types. Although NTA 
includes the possibility of detection of a fluorescence signal from labeled EVs164, this 
expansion of the technique is hampered by rapid bleaching of common 
chromophores141 and fluorescence NTA is still regarded as being in an early stage of 
development171. 
Tunable resistive pulse sensing 
TRPS is based on the Coulter principle, which was first documented by the Coulter 
brothers in 1948176 and applied in the earliest flow cytometers for blood cell counting 
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in the 1950s. The Coulter principle relies on the fact that a particle that is present in 
an electric field in a conductive liquid will change the current flow in the electric field. 
When a part of the current path is constricted, the passage of a particle through the 
constricted area can cause a change in current flow that can be detected and 
measured177. In TRPS, an upper and a lower fluid cell are separated by a non-
conductive membrane with a small aperture, a so-called ‘nanopore’ in it. When the 
upper and lower fluid cell as well as the aperture that interlink them contain a 
conductive liquid and a voltage is applied to the system, a continuous current of ions 
is established and measured as the ‘baseline current’. The sample that contains the 
particles of interest constitutes the conductive liquid in the upper flow cell. When a 
particle passes through the aperture, it causes a brief increase in the impedance of 
the pore, reflected by a transient decrease in current, which is detected by the 
system and represented by a peak-shaped negative deviance from the graphically 
monitored baseline current. The magnitude and rate of these negative peaks are 
used to estimate the sizes and the concentration of the particles166,178. Thus, as in 
NTA, a histogram of particle diameter versus particle concentration is obtained, 
while phenotyping is not. A combination of different forces, including 
electrophoretic and convective flow, cause the movement of particles through the 
nanopore178, and a variable pressure module can be used to add extra force166. 
Different nanopores with different aperture diameters exist and can be selected for 
particular samples according to the expected size range of the particles in the 
sample179, and furthermore the user can adjust the diameter of the aperture by 
changing the stretch of the pore holder178. 
Extracellular vesicle Array 
The EV Array is a recently developed method based on the protein microarray 
technology, which is used for identification of antigens or antibodies in biological 
samples. The EV Array, which has been under development since 2011180 and was 
first documented in a publication from 2013168, is prepared by printing a chosen 
panel of capturing agents, typically antibodies, on epoxy-coated microarray slides. 
The method has been tested with a range of capturing agents enabling capture of 
EVs by binding their surface-associated antigens. Tested capturing agents include 
antibodies against the tetraspanins CD9, CD63, and CD81 that are typically present 
on the surface of exosomes168,181 and annexin V181 which binds PS171. After drying, 
the printed slides are incubated with the sample containing the EVs prior to addition 
of biotinylated detection antibodies. Then fluorescently labeled streptavidin is 
applied and binds to biotin on the detection antibodies. The fluorescence intensity 
from the bound streptavidin, which is determined by a fluorescence scanner, is used 
as a semiquantitative measure of the sample’s content of EV surface molecules that 
bind the capturing and detecting agent used in the EV Array, whereas direct counting 
and size determination of particles are not obtained with this method. As detection 
agents a combination of biotinylated antibodies against CD9, CD63, and CD81 have 
been tested, but also other biotinylated antibodies can be used181. As an open 
platform, EV Array can be modulated for detection of subpopulations such as TF-
bearing EVs182 or subpopulations carrying antigens that reveal their cellular origin. 
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CD146, CD31, and CD62E have been established as markers of endothelial cell origin 
in EV studies183, while CD206 and CD163 are expressed by macrophages and 
dendritic cells184. CD14 exists on monocytes and macrophages and in low levels on 
neutrophils185, while CD42a, CD42b, and CD41 are present in platelet membranes186.    
PREANALYTICAL CONSIDERATIONS 
Blood sampling and plasma preparation 
Regarding blood collection, the use of a tourniquet, venipuncture, and blood flow 
through a needle with a small diameter into a vacuum blood collection tube may 
cause hemolysis, endothelial damage, or platelet activation, which may lead to an 
increase in the EV number and other changes in the population of EVs detected in 
the sample146. If serum is used for EV analysis, over 50 % of the detected EVs may be 
accounted for by platelet-derived EVs released after the blood collection during clot 
formation123. In an ISEV position paper123 it was stated that plasma is the 
physiological medium of EVs in the blood and that most studies on circulating EVs 
had been performed on plasma123 which has been recommended for most 
applications171. The type of anticoagulant used for plasma sampling, the time interval 
between blood collection and centrifugation, and the temperature and agitation that 
the blood is exposed to can affect the results of subsequent EV analysis146,171. 
Meticulous removal of platelets is important since remaining platelets release EVs 
during freezing and thawing of plasma171 but, on the other hand, centrifugation 
required to remove all platelets is likely to also remove large EVs123. EVs in plasma 
seem to be stable during one freeze-thaw cycle, but it has been recommended to 
avoid repeated freeze-thaw cycles171. General recommendations on practical 
preanalytical handling of blood samples for EV analysis were given in a publication 
released by Lacroix et al. at about the time of the beginning of this PhD project187 
and in a recent review on EV analysis171. 
EV isolation 
Apart from preparation of platelet free plasma (PFP) by removal of blood cells and 
platelets, which has been recommended to be done by applying two subsequent 
centrifugation steps of 2500 g for 15 minutes171,187, it would for some purposes be 
desirable to isolate EVs entirely. However, all isolation methods affect the 
concentration of EVs and no method is capable of isolating EVs only171. Typically co-
isolated components include protein aggregates and some types of lipoproteins171.  
A common method of EV isolation is differential centrifugation. This approach allows 
for pelleting EVs and for some degree of separation of large and small EVs but also 
holds considerable limitations since it does not provide complete isolation of EVs 
from protein aggregates and lipoprotein particles and furthermore tends to damage 
EVs during the final ultracentifugation step and result in aggregation of EVs188,189 and 
poor EV recovery171. Density gradient centrifugation enables removal of protein 
contaminants but is time-consuming123,171 and does not provide complete isolation 
of EVs from small lipoproteins190,191.  More recently, a much less time-consuming 
method termed size exclusion chromatography (SEC) was proposed for EV 
 
43 
purification192. While SEC does not tend to induce aggregation or biophysiological 
changes of EVs, it dilutes them and implies coisolation of EVs, protein aggregates, 
and large lipoproteins171. Other isolation methods that may be applied include 
filtering although it may damage EVs123, precipitation although it is unable to isolate 
pure EVs, and immunocapture which may be used to capture subpopulations of 
EVs171. 
Regarding the unfavourable side effects of attempts of EV isolation, Mooberry et al. 
recommended that FC-based EV analysis should be performed on plasma146. 
ANALYTICAL CONSIDERATIONS 
While the above described techniques for EV analysis can provide indications of the 
amounts, sizes, and phenotypical characteristics of EVs in a solution, the data 
obtained by their use needs to be interpreted with reservations. 
The heterogeneity of EVs present in a biological sample can be illustrated by the 
proposition that the smallest and the largest of them typically differ 25-fold in size, 
300,000-fold in concentration, 20,000-fold in volume, and 10,000,000-fold in light 
scattering properties, which complicates exact EV enumeration193. Light scatter-
based methods for EV measurement, such as FC and NTA, are also challenged by the 
lack of a reference material with a refractive index equalling that of EVs194,195. In FC, 
EV measurements are typically based on scatter signals from polystyrene or silica 
beads although these have a different refractive index than EVs, which inevitably 
compromises both EV size and concentration measurements196. In NTA, the 
measured concentration depends on the brightness of the scattering particles, which 
means that the refractive index, and furthermore the size distribution of the particles 
present in the sample, will affect concentration measurements196. A particle that 
scatters less light than the limit of detection, will not be measured197. For 
standardization of NTA-based as well as FC-based EV measurements a biological 
standard would be desirable195, and attempts to identify candidates for such new 
reference materials are going on196. 
When EVs are analyzed by FC, the possibility of coincidence events, also termed  
‘swarm detection’, exists, meaning that multiple EVs simultaneously passing the 
laser beam are counted as one event, which affects the measured event rate169,198. 
In this way a single small EV, which does not by itself scatter enough light or emit 
enough photons to be detected by light scatter or fluorescence measurement, 
respectively, may together with other EVs generate a signal that exceeds the 
detection threshold141. Flow cytometers differ in optical configuration and 
sensitivity, and as is the case with other methods for EV measurement, 
standardization of FC-based EV measurement has not been obtained, which makes 
data comparison between laboratories problematic141. 
While FC because of its limitations regarding measurement of the smaller EVs, only 
casts light on the tip of the iceberg of the EV population, NTA and TRPS allow for 
some exploration of the ‘bulk’ of the iceberg. However, the concentration 
measurements obtained by these methods still strongly depend on the lower size 
limit of detection141. Since no reference material with the ideal refractive index 
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exists, NTA cannot be accurately calibrated for EV measurment, which implies some 
inherent error in the obtained results. Since the nanopores used in TRPS display 
considerable pore-to-pore variation and the baseline current through a pore varies 
over time, the minimum detected size with TRPS is inconstant178. 
EV Array does not provide size measurements of EVs and as opposed to the other 
three methods described here, it does not detect single EVs. Instead it  
semiquantifies the EVs by means of the overall fluorescent intensities from the 
detection agents bound to the EV-associated proteins present without taking into 
account how many copies of each antibody-bound protein that are present on each 
particle. Also in FC, the amount of the antigen of interest present on a single particle 
is an analytical issue, since only vesicles that carry a sufficient amount to generate a 
detectable fluorescence signal are detected197, and the relationship between the 
detected fluorescence signal and the number of epitopes is complex141. 
While EV Array as well as FC can provide some phenotypical information on the EVs 
in a sample based on fluorescent labeling of proteins, these approaches imply the 
introduction of potential sources of error and variance related to factors such as 
antibody specificity, antibody aggregate formation, low signal-to-background ratio, 
and variability in staining intensity194. Also, it should be noted that no generic label 
for all types of EVs exists141 and the lack of such an invariant ‘household marker’ 
complicates label-based EV quantification168. PS has been used as an MV marker in 
several studies on plasmatic EVs, but a significant number of MVs do not appear to 
be PS-positive119,199, and experimental conditions, such as calcium concentrations 
affect the binding to PS when annexin V is used as a probe200. Lactadherin has been 
demonstrated to be more sensitive than annexin V for PS detection201, and since 
lactadherin binds PS in a calcium independent manner, it has been stated that 
lactadherin can be used to detect PS-exposing MVs directly in citrate-anticoagulated 
plasma samples124. 
Lipoproteins 
Lipoprotein subtypes and functions 
Lipoproteins are particles involved in the transport of lipids between tissues. As 
opposed to EVs, lipoproteins only have a single layer of phospholipids in their 
membrane191, which also contains free cholesterol and different types of 
apolipoproteins, and the surface of a lipoprotein particle resembles the external half 
of a cell membrane202,203. The hydrophilic surface allows for the transport in plasma 
of hydrophobic molecules, namely triglycerides (TGs) and cholesterol esters, 
contained in the hydrophobic core of lipoproteins203. 
Subclasses of lipoproteins termed chylomicrons, chylomicron remnants, very low 
density lipoproteins (VLDLs), intermediate density lipoproteins (IDLs), low density 
lipoproteins, (LDLs), and high density lipoproteins (HDLs) play their different parts in 
the redistribution of dietary lipids in the body via the exogenous and endogenous 
lipoprotein pathway and the reverse cholesterol transport pathway202. 
Chylomicrons are large triglyceride rich lipoproteins (TRLs), each containing one 
apolipoprotein B-48 (ApoB-48) molecule. They are formed in the intestinal cells upon 
absorption of monoacylglycerols, fatty acids, and cholesterol from the intestinal 
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lumen after food ingestion. The diameter of chylomicrons ranges from 75 to 1200 
nm202,204 and they are especially large and TG-rich when a fat-rich meal has been 
consumed202. Upon formation, chylomicrons are secreted into the lymph and via 
ductus thoracicus they reach the circulation where they are metabolized by 
lipoprotein lipase (LPL) present in muscle and adipose tissue. LPL hydrolyzes TG in 
chylomicrons, and the resulting chylomicron remnants have a diameter between 30 
and 80 nm and contain less TG, while they expose apolipoprotein E, which allows for 
receptor-mediated uptake of chylomicron remnants in hepatocytes202. This so-called 
exogenous lipoprotein pathway, starting with the formation of chylomicrons in the 
intestine and ending with their uptake by the liver, normally enables metabolism of 
considerable amounts of dietary fat and transfer of dietary fatty acids to muscle cells 
and adipocytes with only modest resulting increases in plasma TG levels202. 
VLDLs are TRLs, most of which have a diameter between 27 and 60 nm, although  
some of them may have a diameter of up to 200 nm205,206. They are formed in the 
liver in a process that involves transfer of TG and cholesterol esters to apolipoprotein 
B-100 (ApoB-100). VLDLs are secreted from hepatocytes into the blood and reach 
the peripheral tissues where their TG is hydrolyzed by LPL, resulting in their 
transformation into IDLs with a smaller diameter of 23-35 nm202,205,206. IDLs contain 
less TG than VLDLs and are thus relatively enriched in cholesterol esters. IDLs are 
subjected to further TG depletion via hydrolysis and some of their apolipoproteins 
are transferred to other lipoprotein particles resulting in the transformation of the 
IDLs to LDLs, which mainly consist of cholesterol202 and have diameters between 18 
and 23 nm205,206. LDLs are taken up from the circulation by LDL receptors in the liver 
and several other tissues. Throughout this endogenous lipoprotein pathway that 
involves metabolism of VLDLs to IDLs and then LDLs, each of these three subtypes of 
lipoproteins contains exactly one ApoB-100 molecule per lipoprotein particle202. 
In the postprandial phase, the concentration of ApoB-48-bearing particles, which 
include chylomicrons and chylomicron remnants, increase significantly, and the 
concentrations of ApoB-100-bearing particles increase even more207,208.   
The formation of HDLs relies on the synthesis of Apolipoprotein A-I (ApoA-I) which is 
mainly produced in the hepatocytes and enterocytes and then secreted to the 
circulation where it initially acquires cholesterol and phospholipids being effluxed 
from hepatocytes and enterocytes. The thus formed HDLs then also acquire 
cholesterol and phospholipids from cells such as muscle cells and adipocytes, and 
furthermore from chylomicrons and VLDLs from which the HDLs also take up some 
apoliproteins but not ApoB-100202. The cholesterol contained in HDLs, which have 
diameters between 5 and 12 nm202,203, is mainly delivered to the liver. This so-called 
reverse cholesterol transport is necessary for most cell types in order to decrease 
their cholesterol content and is probably important for the prevention of 
atherosclerosis202. 
Interference of lipoproteins on extracellular vesicle analysis 
Since EVs and lipoproteins have overlapping size ranges, and lipoproteins are present 
in plasma in numbers that are probably significantly higher than EV numbers171, it 
seems plausible that lipoproteins may interfere with EV analysis methods that rely 
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on concentration measurement of particles within a given size range, such as NTA 
and TRPS. Dragovic et al. performed studies which indicated that most particles 
detected by light scatter-based NTA of platelet-poor plasma samples are 
lipoproteins164, and Gardiner et al. suggested that lipoproteins account for more 
than 98 % of  the particles detected by NTA in PFP that has not been 
ultracentrifuged195. 
However, even when FC with phenotypical characterization of the detected particles 
is used for EV measurement, the results may be influenced by lipoproteins present 
in the sample. In 2016, Sódar et al. published data showing that most of the particles 
detected by FC in PFP exposed lipoprotein markers in the form of ApoB-100/-48 and 
that such ApoB-positive events highly outnumbered EV marker-exposing events in 
the form of CD9-positive, CD41a-positive, and annexin V-binding events. When 
results on PFP obtained from blood collected in the fasting state were compared with 
results on PFP obtained from blood collected in the postprandial state, it was evident 
that in the postprandial PFP samples the concentrations of ApoB-exposing particles 
were significantly increased, while CD9- and CD41-positive events decreased 
significantly, and PS-positive events decreased unsignificantly191. In the same study, 
when FC was applied on isolated MV preparations obtained from PFP by differential 
ultracentrifugation and gravity driven size filtration, the detected number of annexin 
V-binding events significantly decreased in the postprandial as compared to the 
fasting state. While it had previously been reported that HDL particles co-purify with 
exosomes190, the study by Sódar et al. unexpectedly revealed that ApoB-100-bearing 
particles co-purified with MVs and with exosomes isolated by the abovementioned 
purification techniques. Moreover, when commercially acquired purified LDL was 
mixed in vitro with cell-line derived MVs and exosomes, LDL particles were shown to 
bind extensively to both types of EVs, and it was suggested that binding of 
lipoproteins to EV surfaces may to some degree hinder the detection of EV markers 
in the postprandial state191. 
“How could we miss lipoprotein particles until now? Why did we not detect them 
before?” 
(Sódar et al., 2016)191. 
The quote from Sódar et al. stresses the authors’ amazement of their finding that 
ApoB-bearing lipoproteins co-purify with EVs and may profoundly affect EV 
measurements even when particle phenotyping by FC is applied. 
Surely, the potential effect of blood contents of lipoproteins, and thus prandial state 
at the time of blood sampling, on EV measurements has been a matter of concern in 
this PhD project, reflected in the work presented in paper 1, 2, and 3. 
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AIMS AND HYPOTHESES 
The primary aim of this PhD project was to gain insight into the mechanisms of 
thrombus formation in AF patients. The nomination of procoagulant EVs as a 
potential contributing factor to AF-related thrombogenicity gave rise to a number of 
secondary aims related to the discipline of EV analysis. 
While study 4 was the one that was carried out last, it was the hypotheses of study 
4 that set the scene for the entire body of scientific work performed within the 
framework of the PhD project, and therefore these will be presented first. 
STUDY 4 
Based on the background information that 
 AF is a major risk factor of thromboembolism32 
 The LAA is the most common site of intra-atrial thrombus formation in AF 
patients83 
 AF results in changed blood flow, including reduced flow velocity, in the LAA85 
 The LAA endothelium can be damaged and infiltrated by inflammatory cells in 
AF patients105 
 TF and vWF can be overexpressed in the LAA endothelium in AF patients105 
 Cell stress and activation can induce cellular release of EVs124 
 EVs can have procoagulant capacity, especially subtypes that expose TF154 
we reasoned that conditions which may promote procoagulant EV release and 
accumulation in the LAA lumen appear to be present in AF patients and established 
the hypothesis that:  
Elevated levels of procoagulant EVs exist in blood located in the LAA as 
compared to venous blood in patients with AF. 
However, while some accumulation of procoagulant EVs potentially derived from 
cells in the LAA wall may take place due to blood stasis, the actual extent of blood 
exchange between the LAA lumen and the rest of the circulation is not well-known 
and may be substantial. Furthermore, it is conceivable that AF may induce release of 
EVs to the blood from cells located outside the LAA, such as the main part of the LA. 
Based on these considerations and the previous reports on increased levels of TF102, 
vWF87, and other hemostatic markers87 in venous blood in patients with AF, we also 
hypothesized that: 
Elevated blood levels of procoagulant EVs exist in AF patients as compared 
to subjects without AF. 
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Thus, the aim of this study was to compare the amounts of EVs, including EVs 
exposing TF and markers of platelet, leukocyte, or endothelial cell origin, in venous 
blood and blood drawn directly from the LAA in patients with and without AF. No 
patients with valvular AF were included, because it has been indicated that mitral 
valve disease in itself induces endocardial damage and potentially thrombogenic 
changes in the LAA107. Apart from EVs, we aimed to evaluate levels of circulating TF, 
vWF, PPLs, NETs, and total submicron particles in the collected blood samples. 
OVERALL AIM OF STUDY 1, 2, AND 3 
As it appears from the background section, the field of EV analysis holds several 
challenges and lacks standardization42,141. Thus, in order to pursue the hypotheses of 
study 4, it was necessary to establish, gain experience with, and evaluate strategies 
for EV measurement, which constituted the overall aim of study 1, 2, and 3. 
Considering the background information that 
 plasma is the physiological medium of EVs in blood123 
 remaining platelets in plasma release EVs during freezing and thawing of 
plasma171 
 all isolation methods affect the concentration of EVs and no method is 
capable of isolating EVs only171 
we found it relevant to focus on strategies for EV measurement on PFP instead of 
isolated EVs or customary plasma. 
The specific aims of study 1, 2, and 3 are formulated in the following. 
STUDY 1 
As NTA163 and TRPS179 have been nominated as valuable methods for measurement 
of smaller EVs in biological samples, supplementing methods such as conventional 
FC that may only enable detection of the ‘tip of the iceberg’ of EV populations170, we 
planned to establish NTA and TRPS in our laboratory. However, since lipoproteins in 
the same size range as small EVs195,206 exist in plasma at any given time and are 
especially abundant in the postprandial phase207,208, lipoprotein particles plausibly 
represent a substantial source of interference with EV measurements on PFP by NTA 
and TRPS. By preparing PFP by two centrifugation steps as recommended by Lacroix 
et al.187 we should avoid EV release from platelets during the freeze-thaw cycle. 
However, we found it relevant to examine whether or not freezing and thawing PFP 
prior to measurement would affect the particle population. 
Thus, the aims of study 1 were to  
 evaluate the analytical linearity and analytical variation of submicron particle 
measurements by NTA and TRPS 
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 estimate the inter- and intra-individual biological variation of submicron 
particles in PFP as measured by NTA and TRPS 
 evaluate the impact of a freeze-thaw cycle on the submicron particle population 
in PFP as measured by NTA and TRPS 
 evaluate the impact of prandial state on the submicron particle population in 
PFP samples as measured by NTA and TRPS 
As such, study 1 was of descriptive nature, but the two last-mentioned aims were 
prompted by the underlying hypotheses that: 
A freeze-thaw cycle significantly affects the submicron particle population 
as measured by NTA and TRPS. 
and 
TG-rich lipoproteins appearing in the postprandial state significantly 
increase submicron particle concentrations as measured by NTA and TRPS. 
Furthermore, as part of study 1, we performed an additional investigation on SEC 
fractions of PFP that were relatively enriched in EV content compared to HDL and 
protein content as described by Boing et al.192 In this additional study we aimed to 
examine if particle levels in these particular SEC fractions were affected in the same 
way by food ingestion and a freeze-thaw cycle as the samples in the main study. 
STUDY 2 
As discussed in paper 1209, ApoB-bearing lipoproteins plausibly account for a non-
negligible share of the particles detected by NTA in PFP from fasting blood samples, 
even in EV-enriched fractions obtained by SEC. Hence, we designed and conducted 
study 2 as a proof of concept study210 in which we aimed to explore the potential of 
removing interfering lipoproteins from PFP by use of anti-ApoB antibody-coated 
magnetic beads prior to EV analysis by NTA. 
The corresponding hypothesis was: 
Lipoproteins interfering with EV analysis by NTA can be removed from PFP 
by use of magnetic beads coated with anti-ApoB antibodies. 
STUDY 3 
Bearing in mind that 
 the effect of food intake on the EV population in the blood is not well 
known123, although elevated levels of EVs derived from endothelial cells134 
and platelets135 in the postprandial state have been reported 
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 postprandial coagulation activation has been reported110 
 elevated postprandial levels of circulating TF have been described111 
 lipoproteins may interfere with FC-based EV measurement191 
we conducted study 3 in which we aimed to 
 evaluate the impact of prandial state on PFP concentrations of PS-exposing 
submicron particles as measured by FC, including subtypes staining positive for 
TF or markers of platelet or endothelial cell origin 
 evaluate the impact of in vitro addition of lipoproteins to fasting PFP on PFP 
concentrations of PS-exposing submicron particles measured by FC, including 
subtypes staining positive for TF or markers of platelet or endothelial cell origin 
 evaluate the impact of prandial state on PFP content of EVs as measured by EV 
Array, including subtypes exposing PS, TF, or markers of platelet or endothelial 
cell origin 
 
The corresponding hypotheses were: 
 
Prandial state affects PFP concentrations of PS-exposing submicron 
particles measured by FC, including subtypes staining positive for TF or 
markers of platelet or endothelial cell origin,  
 
In vitro addition of lipoproteins to fasting PFP mimics the effect of food 
ingestion on PFP concentrations of PS-exposing submicron particles 
measured by FC, including subtypes staining positive for TF or markers of 
platelet or endothelial cell origin, 
and 
Prandial state affects PFP content of EVs as measured by EV Array, including 
subtypes exposing TF, PS, or markers of platelet or endothelial cell origin. 
Moreover, we aimed to evaluate TF antigen and TF activity levels in PFP from fasting 
and postprandial blood samples. 
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MATERIALS AND METHODS 
STUDY POPULATIONS 
STUDY 1 AND 3 
The same study population was used for study 1 and study 3. 20 adult subjects (7 
males and 13 females) aged 26-64 years were included after being considered 
healthy, based on a medical questionnaire and blood tests that included hematology 
tests, liver and kidney function tests, and blood glucose levels. 
STUDY 2 
10 healthy individuals (4 females and 6 males) aged 27-60 years were included. 
STUDY 4 
7 patients with paroxysmal, nonvalvular AF (aged 45-81 years), 6 patients with 
persistent or permanent nonvalvular AF (aged 67-76 years), and 12 controls patients 
(aged 48-80 years) without AF were included. The control group and the AF group 
were both comprised of patients who had been referred to either coronary artery 
bypass grafting or aortic valve surgery at the Department of Cardiothoracic Surgery, 
Aalborg University Hospital. 
BLOOD SAMPLING AND SAMPLE HANDLING 
STUDY 1 AND 3 
Blood for study 1 and 3 was sampled from the median cubital vein through a 
Vacuette Safety Blood Collection Set (Greiner Bio-One, Kremsmünster, Austria) with 
a 21 gauge needle and a 19 cm flexible tube after application of a light tourniquet. 
Fasting samples were collected at 8.15 am. At 8.30 am the study participants were 
served a non-standardized breakfast and postprandial samples were collected at 
9.45 am. Blood destined for PFP preparation was collected in 9 mL 3.2 % sodium 
citrate plastic tubes (Greiner Bio-One) after the first 3.5 mL of blood obtained from 
the intravenous access had been discarded. Blood for routine tests, such as lipid 
measurements, was collected into standard tubes for the respective tests at Aalborg 
University Hospital and analyzed on the day of blood sampling. 
PFP was prepared by applying two centrifugations at 2500 g for 15 minutes at room 
temperature. The first centrifugation was initiated within 30 minutes after the blood 
sampling. When collecting supernating plasma for transferal to a clean plastic tube 
after the first centrifugation, 10 mm of plasma was left uncollected above the buffy 
coat. Fresh PFP from all patients was analyzed by NTA and TRPS on the day of blood 
sampling. The remaining PFP was divided into aliquots for the different analyses and 
frozen and kept at -80 °C until the day of analysis. 
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STUDY 2 
In study 2, fasting blood samples were collected and PFP was prepared in the same 
way as in study 1 and 3. PFP was kept at -80 °C until the day of experimental 
lipoprotein removal and analysis. For removal of ApoB-exposing lipoproteins from 
PFP, we established the ‘bead procedure’ in which PFP was incubated with anti-ApoB 
antibody-coated magnetic beads (prepared as described under ‘Additional 
materials’) and mixed under rotation for 120 minutes, allowing for antibody-based 
binding of the magnetic beads to VLDL, LDL, and IDL particles, and chylomicrons. 
Following this incubation, PFP was separated from the beads by use of a DynaMag-
2 (Life Technologies, Carlsbad, CA, USA) magnet before analysis. 
Blood for measurement of lipid levels was collected into standard tubes for these 
tests at Aalborg University Hospital and analyzed on the day of blood sampling. 
STUDY 4 
In study 4, 3.5 mL Vacuette 3.2 % sodium citrate plastic tubes (Greiner Bio-One, 
Kremsmünster, Austria) were used for pre- and intraoperative collection of blood for 
PFP preparation. All study participants were preoperatively fasting at the time of 
blood sampling. Immediately before commencement of surgery, 3 tubes of venous 
blood for PFP preparation were sampled from a central vein via a central venous 
catheter. After sternotomy, but immediately before systemic heparinisation, 
another 3 tubes of central venous blood were sampled intraoperatively along with 3 
tubes of blood sampled through a cannula which was inserted in the LAA. A 75 cm 
Luer Lock Extension tube (Praxisdienst, Longuich, Germany) interlinked the cannula 
and the blood sampling tubes. PFP was prepared in the same way as in study 1, 2, 
and 3, except that the time period between blood sampling and initiation of first 
centrifugation was up to 60 minutes. NTA analysis was performed on the day of 
blood sampling, while PFP for the remaining analyses was kept at -80 °C until the day 
of analysis. Blood for measurement of plasma lipid levels was collected before 
surgery into standard tubes for these tests at Aalborg University Hospital and 
analyzed on the day of blood sampling. 
BLOOD ANALYSIS 
NANOPARTICLE TRACKING ANALYSIS 
NTA was performed in study 1, 2, and 4. In all three studies the same NTA instrument, 
settings, and work routines were used. The applied NTA device was a  
LM10-HS (Malvern Instruments Ltd, Malvern, UK) with a Luca DL-658M-OEM EMCCD 
camera (Andor Technology, Belfast, UK) and a 405 nm laser. NanoSight NTA 2.3 was 
used for data processing. As PFP samples were diluted several hundred times in 
Dulbecco’s Phosphate Buffered Saline (DPBS) (Lonza, Basel, Switzerland) when 
analyzed by NTA, sample viscosity was set to the corresponding viscosity for water 
at the given room temperature. Samples were loaded manually with a syringe into 
the sample chamber. The microscope field of view was positioned in the area where 
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the particles were most clearly visualized and video recordings with a length of 60 
seconds were made. Background signal was subtracted before processing. The 
camera shutter was set to 500, camera gain to 300, and detection threshold to 3. 
With regard to minimum track length, blur, and minimum expected particle size 
automatic settings were selected. 
TUNABLE RESISTIVE PULSE SENSING 
TRPS was applied in study 1 and was performed using a qNano (Izon, Oxford, UK). An 
NP200 nanopore (Izon) was mounted and kept at a constant 47 mm stretch during 
analysis. A constant pressure of 7 cm H2O was applied on the system. A qNano 
CPC200B microsphere concentrate (Izon) which had been diluted 1000-fold in 
filtered DPBS was used for calibration. Measurements were continued for at least 
180 seconds or until at least 500 particles had been detected. Baseline current during 
analysis was between 70 and 150 nanoampere. 
APOLIPOPROTEIN B ASSAY 
In study 2, ApoB was quantified before and after the experimental removal of ApoB-
exposing lipoprotein particles by applying Apolipoprotein B (APOB) Human ELISA kit 
(Abcam, Cambridge, UK) and measuring the absorption at a wavelength of 450 nm 
using a SpectraMax M2 Microplate Reader (Sunnyvale, CA, USA). 
EXTRACELLULAR VESICLE ARRAY 
EV semiquantification by EV Array was performed in study 2, 3, and 4, based on the 
method originally described by Jørgensen et al.168 
In study 2, the applied EV Array featured a mixture of antibodies against CD9, CD63, 
and CD81, i.e. the so-called ‘exosome cocktail’, both as capturing and detecting 
agents and was used to estimate the extent of a potential loss of small EVs as a side 
effect of lipoprotein removal. 
In study 3, capturing agents included lactadherin and antibodies against CD9, CD63, 
CD81, CD41, CD146, CD62E, and TF, while the exosome cocktail was used as 
detecting agent. With this design, we aimed to estimate the amounts of EVs exposing 
CD9, CD63, and CD81 in general and subtypes that also exposed PS, TF, or markers 
of platelet or endothelial cell origin, in the fasting and postprandial state. 
In study 4, a broader panel of capturing agents was applied. These included 
antibodies against CD9, CD63, CD81, and annexin V along with a range of antibodies 
against cell type-specific CD molecules, including CD42a, CD42b, CD41, CD31, CD146, 
CD62E, CD206, CD163, and CD14, and moreover two clones of anti-TF antibodies (the 
TF9-10H10 clone and the HTF-1 clone, respectively). A combination of antibodies 
against CD9 and CD81 was used as detecting agents. With this version of EV Array 
we aimed to compare levels of tetraspanin-bearing EVs, and subtypes exposing PS, 
TF, and markers of platelet, endothelial cell, or leukocyte origin. Parallelly, we 
applied an additional version of EV Array with the abovementioned range of 
antibodies against cell type-specific CD molecules as catching agents, combined with 
anti-TF antibodies as detecting agent in order to study which cell types may 
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contribute to PFP content of TF-bearing EVs. Both of these versions of the EV Array 
were applied on PFP from pre- and intraoperative venous blood samples as well as 
PFP from blood samples drawn directly from the LAA in both the AF patient group 
and the control group. 
FLOW CYTOMETRY 
FC was applied in study 3 using a BD FACSAria III High Speed Cell Sorter (BD 
Biosciences, San Jose, CA) and applying an approach that was based on a method 
previously described by Nielsen et al.167 TruCount™ tubes (BD Biosciences) with a 
lyophilised pellet releasing a known number of fluorescent beads serving as an 
internal standard enabling determination of particle concentration were used. 
Fluorescein isothiocyanate-conjugated lactadherin was applied as a marker of PS-
positive events. To identify PS-positive events that also exposed platelet markers, 
particles were further labeled with 3 µL of allophycocyanin-conjugated anti-CD41 
antibodies. Phycoerythrin (PE)-conjugated anti-CD146 antibodies, and PE-
conjugated anti-CD62E antibodies, respectively, were added to label PS-positive 
particles which also carried markers of endothelial cell origin. TF-exposing events 
were identified by labeling with PE-conjugated anti-TF antibodies. Isotype controls 
that matched the respective antibodies against the abovementioned proteins were 
applied as negative controls. By use of a blend of size-calibrated fluorescent 
polystyrene beads with sizes ranging from 0.2 to 0.9 μm, a size gate in a FSC and SSC 
setting allowing for detection of particles with a diameter of approximately 0.2–1.0 
µm, was established. FC was performed with a maximal analysis rate of 20,000 
events per second and each run was ended when event counts reached 500,000. 
TISSUE FACTOR ACTIVITY ASSAY 
For TF activity measurements, which were performed in study 3 only, Tissue Factor 
Human Chromogenic Activity Assay Kit (Abcam) was applied, and the absorbance at 
a wavelength of 405 nm was measured using the SpectraMax M2 Microplate Reader. 
TISSUE FACTOR ANTIGEN ASSAY 
TF antigen concentrations were measured in study 3 and 4 with Imubind anti-human 
Tissue Factor ELISA (Sekisui Diagnostics, Lexington, MA, USA) applying the 
SpectraMax M2 Microplate Reader for absorbance measurement at a wavelength of 
450 nm. 
In study 3, an additional method for TF antigen measurement, represented by a 
modified version of EV Array with anti-TF antibodies as both capturing and detecting 
agents, was applied. 
PROCOAGULANT PHOSPHOLIPID DEPENDENT CLOTTING TIME 
To evaluate the content of PPL in PFP in study 3 and study 4, STA Procoag PPL 
(Diagnostica Stago, Asnières, France) was run on a STA-Compact Coagulation 
Analyzer (Diagnostica Stago). In this assay, the clotting process in a mixture of the 
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PFP sample of interest and human plasma from which the procoagulant 
phospholipids have been removed is iniatied by addition of activated bovine FX. The 
PPL-dependent clotting time (PPL-CT) is measured and reported as the test result.   
VON WILLEBRAND FACTOR ASSAY 
In study 4, the concentrations of vWF antigen in PFP were measured with vWF Ag 
(Siemens Healthineers, Erlangen, Germany) on a Sysmex CS2100i (Siemens 
Healthineers). 
CIRCULATING CELL FREE DEOXYRIBONUCLEIC ACID ASSAY 
In study 4, PFP concentrations of cell free DNA (cf-DNA) were determined as a 
surrogate measure of NETs. DNA was labeled with SYTOX Green nucleic acid stain 
(Thermo Scientific, MA, USA) in a Nunc 96-Well Polypropylene MicroWell Plate 
(Thermo Fisher). Light at a wavelength of 485 nm was applied for excitation. Emission 
at a wavelength of 520 nm was detected with a FLUOstar OPTIMA microplate reader 
(BMG LABTECH, Ortenberg, Germany). 
ROUTINE BLOOD TESTS 
Lipid levels in study 1, 2, 3, and 4 were measured on a Cobas 8000 Modular Analyzer 
(Roche Applied Science, Penzberg, Germany). Supplementary glucose 
measurements and routine liver and kidney function tests for study 1 and 3 were 
also measured on the Cobas 8000, while hematology tests were performed on an  
Advia 2120 Hematology System (Bayer Healthcare, Leverkusen, Germany).  
ADDITIONAL MATERIALS 
COLUMNS FOR SIZE EXCLUSION CHROMATOGRAPHY 
In study 1, SEC was performed using 10 mL qEV columns (Izon). After washing the 
qEV column with 10 mL of DPBS, 0.5 mL of PFP was loaded followed by elution with 
DPBS, and 0.5 mL fractions were collected. Fraction 9 and 10 were expected to be 
relatively EV-enriched, i.e. the HDL and protein content was expected to be markedly 
more reduced than EV concentration, as reported by Böing et al192. 
POLYSTYRENE BEAD SOLUTIONS FOR TRPS VARIATION STUDY 
In study 1, as a supplement to the TRPS between day variation study on PFP, an 
additional between day variation study on a microbead solution consisting of qNano 
SKP200B polystyrene microsphere concentrate (Izon) diluted in filtered DPBS was 
performed. 
LOW DENSITY AND VERY LOW DENSITY LIPOPROTEIN ISOLATES 
In study 2, Human Low Density Lipoprotein (LDL) 5 mg/mL and Human Very Low 
Density Lipoprotein (VLDL) 1 mg/mL (Kalen Biomedical, Montgomery Village, MD, 
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USA), diluted in filtered DPBS to a concentration within the linear range of NTA 
concentration measurement, were used for testing the efficacy of the magnetic bead 
procedure for lipoprotein removal.  
In study 3, the same lipoprotein isolates from Kalen Biomedical were used for in vitro 
addition of lipoproteins to PFP obtained in the fasting state. The LDL isolate was 
added in amounts that had been demonstrated to increase TG concentration by 0.1 
mmol/L and cholesterol concentration by 2.2 mmol/L. The VLDL isolate was added 
in amounts that had been demonstrated to increase TG concentration by 0.2 mmol/L 
and cholesterol concentration by 0.2 mmol/L. 
ANTI-APOLIPOPROTEIN B ANTIBODY-COATED MAGNETIC BEADS 
Prior to the lipoprotein removal step in study 2, the anti-ApoB antibody-coated 
magnetic beads used in study 2 were prepared in our laboratory. In brief, Dynabeads 
Protein G 30 mg/mL (Life Technologies, Carlsbad, CA, USA) were transferred from 
the stock solution to a microtube (Sarstedt, Nümbrecht, Germany). By use of the 
DynaMag-2 magnet, the beads were separated from the solution, and the 
supernatant was removed. Polyclonal anti-human Apoliprotein B-48/-100 antibodies 
1 mg/mL (Meridian, Life Science, Inc., Memphis, TN, USA) were diluted in DPBS with 
0.02 % Tween-20 (Bio-Rad, Hercules, CA, USA) and incubated with the magnetic 
beads under rotation for 10 minutes. During this incubation period, fragment 
crystallizable (Fc) regions of the antibodies bind to Protein G on the beads. The 
hereby prepared antibody-coated beads were then separated from the solution by 
use of the magnet, and the solution was discarded. Next, the antibody-coated beads 
were washed three times, using DPBS with 0.02 % Tween-20, before a final 
application of the magnet and removal of the DPBS used for the third wash. 
STATISTICS 
In all four studies, the Wilcoxon matched pairs signed rank test was used for paired 
data analysis such as analyte levels in the fasting versus the postprandial state, 
particle concentrations before versus after the bead procedure, and analyte levels in 
intraoperative samples drawn from the LAA versus venous samples. 
For correlation analysis Spearman’s correlation was applied in all four studies. 
In study 3, we also applied parametric comparison and correlation methods, namely 
paired t-test and Pearson’s r, based on the Anderson-Darling test for normality.   
For comparison of independent groups, i.e. the AF patient group versus the control 
group in study 4, the Mann-Whitney U test was used. 
Two-sided p-values were given, and p-values below 0.05 considered statistically 
significant. 
In study 1, The 95 % reference intervals were estimated using parametric analysis of 
log-transformed and untransformed data for particle concentration and particle size 
data, respectively. For evaluation of analytical linearity, linear regression was 
performed on measured concentrations plotted against expected concentrations. 
Expected concentrations were calculated as the mean of all raw concentrations of 
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measurements within the ranges considered linear, based on visual assessment, 
divided by the dilution factor. 
In study 1 and 3, pooled CVs were calculated as the square root of the mean of the 
squared CVs. 
Software applied for statistical analysis was R version 3.1.1 for Windows (R 
Foundation for Statistical Computing, Vienna, Austria), Analyse-it version 2.24 
(Analyse-it Software Ltd, Leeds, UK), and GraphPad Prism, version 6.01 (GraphPad 
Software, Inc., La Jolla, CA, USA). 
ETHICAL CONSIDERATIONS 
Study 4 occasioned ethical considerations with regard to potential risks and 
inconveniences for the AF patients and the control patients. After sternotomy blood 
was drawn from the LAA via a cannula inserted at the base of the LAA. Insertion of 
the cannula entailed a minimal risk of bleeding. In case of bleeding, the surgeon 
would suture the cannula insertion site with a single suture and the bleeding volume 
would be maximally a few mL. Venous blood from AF patients and control patients 
was drawn through a central venous catheter and thus did not necessitate 
venipuncture. Apart from the blood samples, LAAs routinely removed from AF 
patients during cardiac surgery in order to prevent thromboembolism, and a small 
piece of RAA tissue from both AF patients and control patients routinely removed 
from patients connected to the cardiopulmonary bypass machine (heart-lung 
machine) were collected and stored in a biobank in preparation for future studies. 
As these pieces of atrial appendage tissue were removed from the patients 
independently of study participation, it did not entail additional health risk for the 
patients. 
The results obtained during study 4 did not affect the individual therapy of the 
participating patients, so the included patients did not benefit directly from 
participating in the study. However, the potential benefit of identifying possible 
novel biomarkers for risk of thromboembolism in the increasing group of AF patients 
was considered to outweigh the risks and inconveniences for the included patients. 
The patients received written information on the study after the decision to undergo 
coronary artery bypass grafting or aortic valve surgery had been made. Oral 
information on the study was given with the room door closed by a cardiothoracic 
surgeon on the day the patient arrived at the Department of Cardiothoracic Surgery. 
The patients were offered time for deliberation regarding informed consent until the 
evening of the day before the procedure was performed and were informed that 
they had the right to withdraw the informed consent at any time. 
Participants in study 1, 2, and 3 underwent an overnight fast and venipuncture of the 
median cubital vein. The participants were informed that venipuncture entails a 
minimal risk of infection, hematoma, and nerve lesion. 
The studies were approved by the The North Denmark Region Committee on Health 
Research Ethics and The Danish Data Protection Agency. 
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RESULTS 
STUDY 1 
ANALYTICAL LINEARITY 
We observed linearity with a coefficient of determination (R2) of above 98 % within 
the particle concentration range of 1.0-10.0 x 108 for NTA and within the particle 
concentration range of 1.0 x 108 – 1.8 x 109 particles/mL for TRPS. 
ANALYTICAL VARIATION 
Nanoparticle tracking analysis 
We found a between-day coefficient of variation (CV) of 6.4 % for particle 
concentration and 9.3 % for mean particle size in PFP samples. The within-run CV 
was 7.0 % for particle concentration and 6.8 % for mean particle diameter. 
Tunable resistive pulse sensing 
We observed a between-day CV of 24.1 % for particle concentration and 6.1 % for 
mean particle size in PFP, while the corresponding within-run CVs were 5.6 % and 
1.4 %, and within-day CVs were 5.0 % and CVs 1.5 %, respectively. 
In the additional between-day variation study on a microbead solution the CV for 
particle concentration was 5.9 % and the CV for mean diameter was 2.3 %. 
INTER-INDIVIDUAL VARIATION 
Nanoparticle tracking analysis 
Estimated 95 % reference range of particle concentration was 1.4 x 1011 – 1.2 x 1012. 
Estimated 95 % reference range of mean particle diameter was 45.5–76.0 nm. 
Tunable resistive pulse sensing 
Estimated 95 % reference range of particle concentration was 1.8 x 108 – 1.6 x 109. 
Estimated 95 % reference range of mean particle diameter was 178.5–283.2 nm. 
INTRA-INDIVIDUAL VARIATION 
Nanoparticle tracking analysis 
Within-subject CV for particle concentrations was 33.6 %. 
Within-subject CV for mean particle diameter was 16.2 %. 
Tunable resistive pulse sensing 
Within-subject CV for particle concentrations was 20.9 %. 
Within-subject CV for mean particle diameter was 10.3 %. 
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FASTING VERSUS POSTPRANDIAL SAMPLES 
Nanoparticle tracking analysis 
In all study participants, we observed higher particle concentrations in PFP from the 
postprandial blood sample than from the fasting sample. The median postprandial 
increase in particle concentration in the fresh samples was 61%. 
Also, a significant increase in mean particle diameter was observed. The median of 
the mean particle diameters in all participants was 62 nm in the fasting samples, 
while in the postprandial samples it was 93 nm. 
Tunable resistive pulse sensing 
Also with TRPS we measured higher particle concentrations in the postprandial as 
compared to the fasting PFP in all study participants, and the changes were much 
more pronounced than those observed with NTA. Thus, the median postprandial 
change in particle concentration in the fresh samples was a 14-fold increase. No 
change in mean particle diameter was observed. 
Lipid levels and their correlation with particle concentrations 
The TG concentration displayed a statistically significant postprandial increase, with 
the median concentration increasing from 1.0 to 1.2 mmol/L after food ingestion. 
Cholesterol levels were not significantly changed. 
In the postprandial samples TG levels significantly correlated with particle 
concentrations measured by NTA (rs = 0.85) as well as TRPS (rs = 0.80). In the fasting 
samples TG levels more moderately yet statistically significantly correlated with 
particle concentrations measured by NTA (rs = 0.50), while there was no significant 
correlation between TG levels and particle levels measured by TRPS. 
Cholesterol levels did not significantly correlate with particle concentrations 
measured by neither NTA nor TRPS. 
FRESH VERSUS THAWN SAMPLES 
Nanoparticle tracking analysis 
Significantly higher particle concentrations were seen after one freeze-thaw cycle. In 
the fasting PFP samples, one freeze-thaw cycle resulted in a median increase in 
particle concentration by 29 %. In the postprandial samples the median increase was 
38 %. No changes in mean particle size was observed. 
Tunable resistive pulse sensing 
With TRPS, we observed a median increase in particle concentration by 32 % in the 
fasting samples after one freeze-thaw cycle. No change in concentration was 
observed after freezing and thawing the postprandial samples. With regard to mean 
particle diameter, a median postprandial increase by 11 % in the fasting samples and 
10 % in the postprandial samples, was observed. 
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PFP FRACTIONS OBTAINED BY SIZE EXCLUSION CHROMATOGRAPHY 
The particle populations in the fractions obtained after SEC were analyzed by NTA. 
In SEC fraction 9 and 10 obtained from fasting PFP the particle concentration was 4.1 
x 1010 particles/mL and 3.5 x 1010 particles/mL, respectively. In fraction 9 and 10 a 
mean postprandial increase in particle concentration of 113 % and 62 %, 
respectively, was observed. Applying a freeze-thaw cycle on fraction 9 and 10 of 
fasting PFP resulted in an increase in particle concentration by 43 % and 24 %, 
respectively. 
The mean particle diameter in was 74 nm in fresh fasting PFP samples before SEC, 
while in fraction 9 and 10 it was 81 and 80 nm, respectively. In fresh postprandial 
samples the mean particle diameter was 91 nm in PFP, 104 nm in fraction 9, and 83 
nm in fraction 10. We did not observe a systematic effect of a freeze-thaw cycle on 
mean particle diameter. 
STUDY 2 
EFFECT OF BEAD PROCEDURE ON PARTICLE CONCENTRATION 
Lipoprotein isolates 
The bead procedure was applied on the diluted VLDL isolate and on the diluted LDL 
isolate, resulting in a decrease in particle concentration of 93 % and 91 %, 
respectively. In the VLDL isolate, particles with diameters up to 450 nm were 
observed and in the LDL isolate, particles with diameters up to 250 nm were 
observed. Thus, considerable amounts of particles larger than expected for VLDL and 
LDL particles were detected in the respective isolates. 
Platelet free plasma 
Applying the bead procedure on PFP samples resulted in a significantly reduced 
particle concentration. The median reduction in particle concentration was 62 %. 
Particle reduction was typically accompanied by an increase in mean particle 
diameter in the remaining particles. Thus, the median of the mean particle diameters 
increased from 54.7 nm to 91.7 nm. 
We explored the possibility of applying the bead procedure on less diluted PFP than 
the 1:1000 and 1:500 dilutions that were used in the main study. We found that it 
was possible to go down to a 1:400 dilution of PFP and obtain results on particle 
reductions that were comparable to the reductions observed with the standard bead 
procedure, while particle reductions became increasingly less effective at lower 
dilutions than 1:400. 
As in study 1, particle concentrations correlated significantly with TG concentrations 
but not with cholesterol levels. 
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EFFECT OF BEAD PROCEDURE ON APOLIPOPROTEIN B CONCENTRATION 
Lipoprotein isolates 
Measuring the ApoB content in the diluted lipoprotein isolates before and after 
performing the bead procedure, we observed a reduction in ApoB content by 97 % 
in the diluted VLDL isolate and a reduction by 69 % in the LDL isolate. 
Platelet free plasma 
The ApoB ELISA was applied on four PFP samples before and after the bead 
procedure. Reductions in ApoB content after the bead procedure varied between 93 
% and 97 %. 
EFFECT OF BEAD PROCEDURE ON EXTRACELLULAR VESICLE CONTENT 
Applying the bead procedure on four PFP samples resulted in reductions in EV 
content as measured with the EV Array in all four samples. The median reduction 
was 21 %. 
STUDY 3 
FLOW CYTOMETRY 
Fasting versus postprandial samples 
The measured concentration of total submicron particles in PFP was markedly 
increased after the breakfast meal in all study participants. The median increase was 
1385 %. Total submicron particle concentrations significantly correlated with TG 
levels in the postprandial state (rs = 0.79), while in the fasting state, they did not. 
A statistically significant postprandial increase in the concentration of PS-positive 
particles was observed, the median increase being 63 %. Also, levels of TF-positive,  
CD41-positive, CD146-positive, and CD62E-positive subtypes of PS-positive particles 
were significantly increased postprandially, the median increases being between 49 
and 307 %. Furthermore, levels of TF-positive PS-negative events increased 
significantly after food consumption. 
In vitro addition of lipoproteins to fasting samples 
Four fasting PFP samples were spiked with LDL and parallelly with VLDL isolate. The 
measured concentrations of total submicron particles and total PS-positive 
submicron particles increased three- to four-fold. Subgroups staining positive for TF, 
CD41, CD146, or CD62E, increased by between 8 and 172 %. We also analyzed control 
samples, which underwent an identical procedure except from PFP being replaced 
by additional DPBS. After addition of LDL and VLDL to these control samples, 
substantial amounts of unstained submicron particles were measured, while no 
antibody-labeled subtypes of PS-positive events appeared upon spiking with neither 
LDL nor VLDL. 
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EXTRACELLULAR VESICLE ARRAY 
Measurable amounts of CD41-positive EVs were detected in fasting samples from all 
study participants. PS-positive, CD146-positive, and TF-positive EVs were detected in 
fasting PFP from the majority of the study subjects while CD62E-positive EVs were 
undetectable in most of the samples. Using anti-CD63 antibodies as capturing agents 
fluorescence intensities below the detection limits were observed in nearly half of 
the samples, while anti-CD81 captured detectable amounts of EVs in all samples and 
anti-CD9 did so in PFP from 19 of 20 study participants. 
No systematic differences were observed between EV levels measured in the fasting 
compared to the postprandial samples. 
TISSUE FACTOR ASSAYS 
While TF antigen was detected in all PFP samples, none of the PFP samples displayed 
measurable levels of TF activity. A statistically significant positive correlation 
between the TF ELISA and the additional EV Array-based method for TF-antigen 
measurement was found both in the fasting and, more markedly, in the postprandial 
samples samples (Pearson’s r = 0.73). There were no systematic differences between 
TF antigen concentrations in the fasting as compared to the postprandial samples. 
TF antigen concentrations neither correlated with levels of TF-positive EVs as 
measured by EV Array nor concentrations of TF-positive PS-positive particles 
measured by FC. However, TF antigen concentrations measured with the EV Array-
based method for TF-antigen measurement moderately correlated with total TF-
positive events measured by FC (rs = 0.46).  
PROCOAGULANT PHOSPHOLIPID DEPENDENT CLOTTING TIME 
No systematic changes in PPL-CT were observed when fasting and postprandial 
samples were compared. PPL-CT did not correlate with concentrations of PS-positive 
submicron particles measured by FC. 
STUDY 4 
No significant differences were found between the paroxysmal and 
persistent/permanent AF group, and in the following these two groups are combined 
and referred to as the AF patient group. 
Nor were any significant differences observed between PFP samples from the first 
and the third tube of blood drawn from the LAA. 
PLASMA LEVELS OF TISSUE FACTOR ANTIGEN 
Significantly higher concentrations of TF antigen were measured in pre- as well as 
intraoperatively collected venous samples from AF patients compared with controls. 
The same tendency was observed in the samples drawn from the LAA, although this 
was not statistically significant (p = 0.07). 
In general, there was a trend towards lower TF concentrations in the intraoperative 
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venous and LAA samples than in the preoperative venous samples. This difference 
was statistically significant when comparing levels in the preoperative venous with 
levels in the intraoperative venous samples in the AF patient group. 
PLASMA LEVELS OF VON WILLEBRAND FACTOR 
Higher vWF concentrations were present in the AF patient group than in the control 
group. This difference was statistically significant in the LAA samples as well as in the 
pre- and intraoperative venous samples. When comparing the LAA and the pre- and 
intraoperative samples within each of the two groups, no significant differences 
were found. 
PLASMA LEVELS OF CELL FREE DEOXYRIBONUCLEIC ACID 
In both the AF patient group and the control group significantly higher PFP levels of 
cf-DNA were meausured in the LAA samples and the intraoperative venous samples 
than in the preoperative venous samples. When comparing the AF patient group 
with the control group, no significant differences were observed. 
PLASMA LEVELS OF PROCOAGULANT PHOSPHOLIPIDS 
Neither when comparing the AF patient group with the control group nor when 
comparing the preoperative venous samples, the intraoperative venous samples, 
and the LAA samples any significant differences in PPL-CT were observed. 
PLASMA LEVELS OF SUBMICRON PARTICLES 
No significant differences in concentrations or mean diameter of submicron particles 
measured by NTA were observed neither when comparing the two groups nor when 
comparing preoperative venous samples, intraoperative venous samples, and LAA 
samples within each group. In accordance with the findings in study 1 and 2, particle 
concentrations correlated significantly with TG levels (rs = 0.82). Moreover, in this 
study, particle concentrations correlated with total cholesterol (rs = 0.55) and LDL 
cholesterol (rs = 0.52). 
PLASMA LEVELS OF EXTRACELLULAR VESICLES 
No significant differences between EV levels in LAA blood as compared to venous 
blood were found in patients with or without AF. 
Levels of EVs captured and detected by anti-tetraspanin antibodies were significantly 
higher in AF patients than in control patients in the intraoperative venous samples. 
A similar, but statistically insignificant, trend was seen in the preoperative venous 
samples (p = 0.12) and in the LAA samples (p = 0.10). 
We observed significantly higher levels of tetraspanin-exposing EVs that were also  
annexin V-positive in AF patients as compared to control patients in the pre- as well 
as the intraoperative venous samples with the same but not statistically significant 
tendency (p = 0.05) observed in the LAA samples. 
Levels of EVs captured by anti-CD146 or anti-CD206 antibodies combined with 
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detection by anti-tetraspanin antibodies were significantly higher in AF patients than 
in control patients in pre-, and intraoperative venous samples as well as LAA samples. 
Likewise, significantly higher levels of EVs measured with anti-CD31 as capturing 
antibody combined with detection by anti-tetraspanin antibodies were seen in AF 
patients than in controls with regard to the preoperative venous samples and the 
LAA samples, and in the intraoperative venous samples the same tendency was 
observed, although this was not statistically significant (p = 0.11). When capturing 
with anti-CD163, anti-CD14- (p = 0.06 in the preoperational samples in both cases) 
and to a lesser extent anti-CD41, anti-CD42a, or anti-CD42b (p > 0.17 in all cases) 
antibodies combined with detection by anti-tetraspanin antibodies was performed, 
a statistically insignificant tendency towards higher levels in the AF patient group 
than in the control group was also observed. 
PLASMA LEVELS OF TISSUE FACTOR-BEARING EXTRACELLULAR VESICLES 
No significant differences in levels of TF-bearing EVs in LAA blood as compared to 
venous blood were found patients with or without AF. 
When EVs were captured by anti-TF antibodies of the TF9-10H10 clone combined 
with detection by anti-tetraspanin antibodies, significantly higher levels were found 
in the AF patient group as compared to the control group in the preoperative and 
intraoperative venous samples as well as the LAA samples. When the HTF-1 clone 
was used as capturing antibody the same tendency was seen in all three sample 
types, although it was only statistically significant in the preoperative venous 
samples. 
 
When anti-CD14 antibodies were used as capturing agents combined with anti-TF 
antibodies as detecting agents, significantly higher EV levels were found in the 
preoperative venous samples and the LAA samples from AF patients as compared to 
controls, and the same trend, but statistically insignificant (p = 0.09) was observed 
in the intraoperative venous samples. A statistically insignificant trend towards 
higher EV levels in the AF patients than in the controls was also seen when capture 
by anti-CD31, anti-CD146, or anti-CD206 antibodies were combined with detection 
by anti-TF antibodies. When anti-CD42a, anti-CD42b, anti-CD62E, or anti-CD163 
antibodies were used as capturing agents in combination with anti-TF as detecting 
agent, most PFP samples did not display a measurable signal. Anti-CD41 as capturing 
agent combined with detection by anti-TF antibodies resulted in a detectable signal 
in most samples, while no trend towards differences between the groups was 
observed. 
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DISCUSSION 
In this PhD study we aimed to investigate the potential role of EVs in AF-related 
thrombogenicity. We hypothesized that elevated blood plasma levels of 
procoagulant EVs exist in AF patients as compared to subjects without AF. We 
furthermore hypothesized that elevated blood plasma levels of procoagulant EVs 
exist in the LAA in patients with AF. The theoretical rationale behind these 
hypotheses has been covered in the background section and summarized in the aims 
and hypothesis section. 
The decision to investigate levels of procoagulant EVs in an AF patient group and a 
control group gave rise to considerations on how to measure EVs. Each method of 
EV isolation and analysis holds limitations171. Evaluation of the potential of EVs as 
biomarkers for thrombogenicity entails examination of existing methods for EV 
detection, including investigation of the susceptibility of EV measurement to 
interference from biological variables such as lipoprotein levels. Taking a clinical 
biochemical approach, we therefore aimed to gain hands-on experience and address 
some of the challenges related to EV analysis through establishment and evaluation 
of methods for EV analysis. Operating in a field that is marked by inconsistent 
nomenclature128 and lack of methodological standardization123, the task of method 
establishment and evaluation can appear to be an abyss of uncertainty. We had to 
settle for elucidation of a small selection of issues related to EV analysis, and we 
chose to put a particular focus on interference from lipoproteins. 
MEASUREMENT OF EXTRACELLULAR VESICLES 
STUDY 1 
Analytical issues 
Analytical linearity 
The data in study 1 indicated analytical linearity for NTA within a concentration range 
that allowed most PFP samples to be diluted into the linear range by a 1:1000 
dilution and in all other cases to identify a suitable dilution factor by applying one 
extra dilution procedure. PFP did not need to be diluted to be within the linear range 
of TRPS, but dilution by a factor of 2.5 or 5.0 was preferable in order to avoid 
nanopore clogging. Further dilution of PFP is also a possibility with TRPS, based on 
the linearity study, and would further reduce the risk of nanopore clogging but would 
also extend analysis time and thus increase the possibility of conformational changes 
in the nanopore itself and a resulting change in baseline current during analysis. Our 
linearity data were obtained by measuring a dilution series of PFP and agreed well 
with findings by others on NTA and TRPS linearity in studies on polystyrene bead 
solutions164,211. 
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Analytical variation 
Taken together, the CVs in the analytical variation study indicated acceptable 
precision. While the between-day variation study on PFP displayed a rather high CV, 
this was not the case with the additional between-day variation study on polystyrene 
microspheres, which may indicate that the between-day data on PFP were 
influenced by preanalytical variation that may have to do with freezing or thawing 
the sample. 
Technical considerations 
Because of the lack of an ideal reference material for NTA of biological particles196 it 
is not possible to apply definite accuracy testing of submicron particles in a PFP 
sample. Despite this inherent lack of opportunity to measure absolute 
concentrations, we consider it feasible to perform comparison studies in which 
particle levels in different types of samples such as fresh versus thawed, or fasting 
versus postprandial samples are compared. This viewpoint has been supported in a 
recent publication on NTA212. Throughout study 1, NTA displayed robustness. TRPS, 
on the other hand, is complicated by the tendency of the nanopore to undergo 
changes, possibly due to repeated stretch of the thermoplastic polyurethane 
material, and by a tendency of nanopore clogging especially when analyzing 
modestly diluted PFP. This problem, which has also been noted by other 
investigators179, entails time-consuming troubleshooting procedures and hampers 
the practical applicability of the method in the laboratory. In particular, we 
experienced instability of the nanopores during the start-up of the additional study 
on EV-enriched SEC fractions, which eventually resulted in the decision not to include 
TRPS in that substudy. 
Biological variation of submicron particle levels 
In the light of the limitations regarding NTA’s ability to measure exact concentrations 
of biological submicron particles, determination of the absolute biological variation 
is not possible. Since concentration measurements with NTA depend considerably 
on camera and detection threshold settings213, the estimated reference ranges only 
provide an indication of the submicron particle levels that can be expected when 
analyzing PFP with the chosen settings specified in the materials and methods 
section, using the LM10-HS and NanoSight NTA 2.3. 
TRPS also holds limitations with regard to particle concentration determination. The 
size range of particles that can be measured depends on the given nanopore and 
since the smallest particles present in PFP cannot be measured with any of the 
nanopores available, the biological variation in particle concentration that we 
measured by TRPS applies to the exact size range measured with the chosen 
nanopore. Given that a considerable amount of particles in PFP have diameters 
below the minimum detection limit of the qNano system164,178, the method cannot 
provide an exhaustive overview of the particles in a PFP sample but nevertheless, 
like NTA, it may be used for comparison of the relative particle content within a given 
size range in different sample types. 
The presented reference intervals for submicron particle concentrations in PFP 
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measured by NTA and TRPS with the given equipment and settings are to some 
extent in line with findings by other investigators reporting particle concentrations 
in PFP of 1 - 5 x 1012 particles/mL measured with NTA195 and particle concentrations 
in non-purified plasma of approximately 2 x 108 particles/mL measured with TRPS, 
applying an NP200 nanopore179. 
The estimated intra-individual variation measured with TRPS and especially NTA was 
considerable, displaying within-subject CVs similar to e.g. those of total bilirubin and 
conjugated bilirubin, respectively214. 
Regarding the biological variation related to prandial state, our data supported the 
hypothesis that TG-rich lipoproteins appearing in the postprandial state increase 
particle numbers measured by NTA and TRPS. The fact that NTA has a substantially 
lower detection limit with regard to particle diameter plausibly explains why the 
relative postprandial increase in measured particle concentration is much more 
extensive in TRPS than in NTA, as the particles appearing upon food intake obviously 
contribute relatively more to the population of larger particles than smaller particles. 
The differences in lower detection limit between the two methods also explains why 
NTA shows an increase in mean particle diameter in the postprandial samples when 
NTA is applied, while TRPS does not despite the marked increase in particle 
concentration demonstrated by TRPS. The diameters of many chylomicrons202,204 
and a smaller portion of the postprandially appearing VLDLs205,206 correspond to the 
size range of TRPS with an NP200 nanopore. The finding of stronger correlation 
between particle concentration and TG concentration in the postprandial as 
compared to the fasting state also suggests that postprandially appearing 
lipoproteins represent a considerable part of the higher particle numbers measured 
after food intake.  However, since indications exist that EV concentrations in plasma 
may also increase in the postprandial state110,134,135,215, part of the measured 
postprandial elevation of particle concentrations may be accounted for by EVs. 
Applying NTA on specific SEC fractions which should be relatively enriched in EVs as 
compared to HDLs and proteins192 showed postprandial changes in particle 
concentration and size levels that were similar to the changes observed in the 
original PFP samples. 
Effect of a freeze-thaw cycle on submicron particle levels  
While mean particle diameter measured by NTA was not significantly affected by 
freezing or thawing the samples, the median increase in particle concentration by 
about 30 % that was observed in both NTA and TRPS measurements, indicates that 
it may be preferable to analyze fresh samples. Therefore, the NTA measurements in 
study 4 were performed on fresh samples. 
Link to study 2 
While NTA and TRPS enable detection of particles smaller than the ones that can be 
measured by conventional FC, the indication of a considerable contribution of 
lipoproteins to the measured particle numbers when applying the methods directly 
on PFP, questions the value of using NTA and TRPS for measurement of EVs in PFP. 
Apart from allowing for a wider size range of particles than TRPS, NTA was 
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considerably more robust than TRPS in daily use in the laboratory. 
To further explore the interference of lipoproteins on NTA-based measurement of 
EV levels in PFP, we performed study 2, in which we tested the potential of 
lipoprotein removal by the bead procedure. 
STUDY 2 
Effect of the bead procedure on lipoprotein solutions 
The bead procedure reduced particle concentrations in VLDL and LDL solutions to a 
level, which was lower than the linear range of NTA measurements and also reduced 
the ApoB concentration in the VLDL solution by 97 %. However, it did not reduce the 
ApoB concentration in the LDL solution quite as effectively as 31 % remained after 
the bead procedure. The explanation to this discrepancy between the extent of 
measured particle removal and ApoB removal from the LDL solution may be the 
overlap between the size range of LDL particles206 and the lower size detection limit 
in NTA173-175. Thus a fraction of the LDL particles may not be detectable by NTA and 
the amount of anti-ApoB antibodies used in the bead procedure may not have been 
sufficient to capture all LDL particles. If this is the explanation, it appears that 
especially the smaller LDL particles have a tendency to dodge the antibody-coated 
beads. 
Effect of the bead procedure on platelet free plasma 
When it came to the PFP samples, the bead procedure prompted effective ApoB 
removal, which was accompanied by a median reduction in particle concentration 
by 62 %. Also, we observed an unwanted side effect in the form of a variable 
reduction of EV content. This may result from LDL particles binding to EVs, a 
phenomenon that has been demonstrated in vitro191. Furthermore, we observed a 
general increase in mean particle diameter after the bead procedure. It could be 
speculated that this results from crosslinking of potentially unbound anti-ApoB 
antibodies to ApoB and formation of aggregates between lipoproteins and anti-ApoB 
antibodies. Alternatively, it may have to do with challenges of precise NTA on 
polydisperse samples195 as lipoprotein depletion by the bead procedure may induce 
a change in the relative number of larger particles in the sample. 
Taken together, our results indicate that removal of ApoB-bearing lipoproteins from 
PFP can be achieved by use of anti-ApoB antibody-coated magnetic beads, while 
other effects on the samples, including variable EV-removal and an increase in the 
measured amount of larger particles are also observed. It should also be mentioned 
that even after removal of ApoB-exposing lipoproteins, HDL particles in PFP may 
interfere with NTA measurements of EVs. It may be possible to further develop and 
optimize the bead procedure, e.g. via testing other antibody clones. While HDL 
particles are expectedly too small to be measured by NTA, it is conceivable that HDL 
particles can form aggregates with each other or with EVs, thus affecting 
concentration and size distribution results. It may be possible to remove HDL 
particles from PFP by a similar procedure, by substituting or supplementing anti-
ApoB antibodies with anti-ApoA-I antibodies. 
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Link to study 3 
While NTA provides robust measurement of submicron particles in PFP, it does not 
enable detailed characterization of the detected particles, such as identification of 
EV markers and thus distinction of EVs from lipoproteins. The interference of 
lipoproteins may be reduced by the bead procedure presented in study 2, but the EV 
population is also affected, and moreover protein aggregates123 in the EV size range 
may represent a non-negligable source of interference. In this PhD project, we had 
a particular interest in the possibility of measurement of TF-bearing EVs, which we 
wanted to apply in study 4. Therefore, we conducted study 3, in which we tested FC- 
and EV Array-based measurement of EVs exposing TF and markers of cellular origin 
and the influence of prandial state on the results. 
STUDY 3 
Flow cytometry 
The 1385 % increase in total particle concentration measured by FC in the 
postprandial phase agreed well with the 14-fold increase in particle concentration 
measured with TRPS in study 1, conceivably because FC and TRPS detect particles in 
roughly similar size ranges. While the postprandial increase in total particles can be 
explained by the appearance of chylomicrons in the postprandial phase, the 
significant increase in PS-positive particles and all measured subtypes as well as PS-
negative TF-positive particles prompts further consideration. Although elevated 
postprandial levels of EVs derived from endothelial cells134 and platelets135 have 
previously been reported, we speculated that an artefactual effect of postprandially 
appearing lipoproteins may account for at least some of the increase in measured 
levels of antigen-exposing PS-positive particles. The finding that in vitro addition of 
commercially acquired LDL particles or VLDL particles to fasting PFP also resulted in 
increased levels of subtypes of PS-positive particles and subtypes staining positive 
for TF, CD41, CD146, or CD62E supported that theory. As many EVs below the lower 
size limit of detection by FC exist, a possible mechanism of lipoprotein interference 
could be simultaneous passing of one or more EVs too small to be detected by 
themselves and one or more lipoproteins through the detecting system of the flow 
cytometer. This could imaginably result in a variant of swarm detection in which 
lipoproteins act as vehicles for vesicles to become 'visible' by FC. The tendency of 
lipoproteins and EVs to pass the laser beam in the flow cytometer simultaneously 
may be enhanced by the tendency of LDLs to adhere to EVs in vitro191. 
Extracellular vesicle Array 
While it has been stated that cells do not release TF-bearing EVs under non-
pathological conditions216, the existence of TF-bearing EVs in the circulation in 
healthy persons has been described150,217. Our EV Array results also indicated the 
presence of TF-bearing EVs in PFP from healthy individuals. Neither the levels of TF-
bearing EVs nor any other measured subtype of EVs measured by EV Array were 
significantly changed by food intake and thus seemingly not considerable affected 
by lipoprotein content in the samples. The observation that in many samples 
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capturing with anti-CD63 antibodies did not result in a detectable fluorescence 
intensity are in line with findings by Pugholm et al.218 who suggested that CD63 may 
be a poor marker for small EVs in general. 
Tissue factor assays 
The absence of TF activity levels above the limit of detection in any PFP samples is in 
line with the findings by others on a healthy population111,219. While measurement 
of TF antigen may not exclusively measure active TF, our results did not indicate 
systematic changes in TF antigen levels in the postprandial as compared to the 
fasting state. Neither did levels of TF-positive EVs measured by EV Array change 
postprandially. Taken together, these findings and the data on PFP samples spiked 
with lipoproteins, are in accordance with the theory of a lipoprotein-induced swarm 
detection-like interference on the FC results on TF-positive events. 
Procoagulant phospholipid dependent clotting time 
While the number of PS-positive events measured by FC increased postprandially 
this was not reflected in shortened PPL-CT, which is in accordance with findings by 
Tushuizen et al.110 and furthermore with the suggestion that the increased 
concentrations of PS-positive particles measured by FC may reflect increased 
interference from lipoproteins rather than increased EV levels in the postprandial 
state. 
Link to study 4 
In study 4, we applied the EV Array and the TF ELISA that we gained experience with 
in study 3. Aware of the fact that different clones of TF antibody have different TF 
binding characteristics220, we applied two different clones of TF as capturing agents 
in the EV Array in study 4. We also intended to apply FC on the PFP samples in study 
4, and the Department of Clinical Biochemistry, Aalborg University Hospital, recently 
established small particle FC, enabling measurement of particles with a diameter 
down to 100 nm in PFP221. However, due to recurring technical problems, it has not 
yet been possible to apply that method on the AF patient and control samples. 
ATRIAL FIBRILLATION AND PROCOAGULANT AGENTS 
STUDY 4 
Venous versus left atrial appendage blood samples 
Our data did not support the hypothesis on elevated levels of procoagulant EVs in 
the LAA blood as compared to venous blood in patients with AF. However, a mean 
luminal LAA volume of 5.4 mL with a standard deviation of 3.7 mL in patients with 
nonvalvular AF has been reported103. Thus, as a blood volume of 3.5 mL was drawn 
into the first tube of blood collected from the LAAs in our study, some admixture of 
blood from the rest of the circulation has in all probability occurred in at least some 
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of the LAA blood samplings from the AF patients, and we cannot exclude the 
possibility that this has camouflaged differences between the sample types. 
Pre- versus intraoperative blood samples 
In a recent review it was noted that circulating cf-DNA can origin from varied sources, 
including cell death(46), and in our study the higher intra- than preoperative levels 
plausibly result from sternotomy-induced cell damage and possibly also sterile 
inflammation. 
The lower TF antigen levels in the intra- as compared to the preoperative PFP 
samples may conceivably result from TF consumption or a configurational change in 
the blood-borne TF upon activation of the coagulation system following sternotomy. 
Atrial fibrillation patients versus controls 
Extracellular vesicle levels 
The EV Array results on tetraspanin-positive, annexin V-positive, CD31-positive, 
CD146-positive, and CD206-positive EVs, indicate that AF is associated with 
increased levels of EVs, including subtypes derived from endothelial cells, 
monocytes, and macrophages. The similar, although statistically insignificant trend 
observed for CD14-exposing EVs and CD163-exposing EVs underpin the suggestion 
that EVs of the monocyte-macrophage lineage are more abundant in AF patients, 
while levels of EVs positive for the additional endothelial cell-marker, CD62E did not 
differ between AF patients and controls. To our knowledge, levels of EVs derived 
from leukocytes in AF patients as compared to patients wihout AF have not 
previously been investigated. Our findings on annexin V-positive EVs are in line with 
the findings by Ederhy et al.161 on higher plasma levels of PS-positive EVs in AF 
patients as compared to a control group without and a control group with 
cardiovascular risk factors. Ederhy et al. also demonstrated higher levels of CD31-
positive EVs in nonvalvular AF patients as compared to a control without 
cardiovascular risk factors while the levels in the nonvalvular AF patients were similar 
to a control group with cardiovascular risk factors. With regard to platelet-derived 
EVs, higher levels have been reported in blood from AF patients than controls 
without cardiovascular risk factors160-162, while levels were similar when comparing 
AF patients to a control group with cardiovascular risk factors160,161. 
Our data on TF-positive EVs, both when applying the TF9-10H10 clone and the HTF-
1 clone as capturing agents, clearly indicate that AF is associated with higher 
concentrations of TF-bearing EVs, which probably at least partly explains the 
elevated levels of blood-borne TF antigen in AF patients102. Furthermore, our data 
on EVs positive for both CD14 and TF suggest that the increased levels of TF-bearing 
EVs in AF patients to some extent depends on release of TF-bearing EVs from cells of 
the monocyte-macrophage lineage. 
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Additional analyses 
Our demonstration of significantly higher concentrations of vWF in AF patients than 
controls are in line with previous reported data by other investigators87. 
Our data on blood-borne TF levels as measured by ELISA in AF patients complement 
previous findings by Chung et al., who demonstrated higher levels of TF in AF patients 
than in a healthy control group but similar levels of TF in AF patients and a control 
group with coronary artery disease102, not specifying if the AF group included both 
valvular and nonvalvular AF patients. 
The absence of differences between cf-DNA levels in AF patients as compared to 
controls suggest that NETs are not an important factor in AF-related 
thrombogenicity. Nor did we find differences in PPL-CT levels despite the observed 
differences in EV levels. Thus, it is a recurring observation that no plain relationship 
between EV levels and amounts of measurable PPLs, such as PS, exists110. 
The correlation between the NTA-based particle counts and the lipid levels 
substantiate the findings in study 1 and study 2 regarding considerable influence of 
lipoprotein content on submicron particle measurement. 
CONCLUSIONS 
In study 1, we found that the performance of NTA as well as TRPS was acceptable 
regarding analytical linearity and variation, while daily use of TRPS was cumbersome, 
primarily due to nanopore instability. Applying NTA and TRPS on PFP, an appreciable 
inter- and intra-individual variation in particle concentration and mean particle size 
was observed. Particle concentration and size distribution were affected by a freeze-
thaw cycle and substantially affected by food intake, the latter probably due to 
appearance of TG-rich lipoproteins in the postprandial state. Correlation analysis in 
study 1, as well as study 2 and 4, indicated that particle concentrations in fasting PFP 
measured by NTA were influenced by lipoprotein content. 
In study 2, we demonstrated that clearing of lipoproteins from diluted PFP by 
application of anti-ApoB antibody-coated magnetic beads prior to NTA appears to be 
achievable, while decreased EV content and increased levels of relatively large 
particles measured by NTA were also observed after application of the bead 
procedure. 
In study 3, we demonstrated that food intake prompted elevated levels of PS-
positive particles, including TF-, CD41- , CD146-, and CD62E-positive subtypes, in PFP 
measured by FC. A similar increase in PS- and antigen marker-positive particles was 
observed upon in vitro addition of LDL or VLDL to fasting PFP, indicating that plasma 
lipoproteins affect FC measurements of these analytes. Thus, the interplay between 
EVs and lipoproteins should be considered when applying FC-based measurement of 
PS-positive particles, and subgroups exposing specific antigens, as an approach to EV 
measurement. EV levels as measured by EV Array were not changed by food 
consumption. 
In study 4, we demonstrated elevated levels of vWF, TF, and EVs positive for markers 
of leukocyte and endothelial cell origin in AF patients as compared to controls. 
Furthermore, we observed higher levels of TF-bearing EVs, including TF-bearing EVs 
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of the monocyte-macrophage lineage, in AF patients than in controls, suggesting that 
AF-related release of TF-bearing EVs at least partially explains the increased levels of 
circulating TF antigen in AF patients. We did not find different levels of EVs, including 
TF-bearing EVs, in LAA blood as compared to venous blood in patients with AF. EVs 
are considered to possess procoagulant capacity and may be mechanistically 
involved in increased thrombogenicity in AF patients. 
PERSPECTIVES 
Science never solves a problem without creating ten more. 
George Bernard Shaw (1856-1950)222.  
The provided data on method performance, possible sources of error in EV analysis, 
proof of concept of antibody-mediated lipoprotein removal, and elevated levels of 
TF-bearing EVs in AF patients may give rise to more questions than answers, but 
hopefully in that way, they represent useful stepping stones to scientific progress 
that can eventually be of benefit to patients. 
EV research is still regarded as a young field122,171, and the need for standardization 
of methodology and technology is increasingly recognized. Development of 
improved methods for EV purification and analysis are expected to help move the 
field forward122, and ISEV and the International Society on Thrombosis and 
Haemostasis recently joined forces to standardize FC-based EV detection171. Our 
results in Study 3 supplemented the findings by Sódar et al.191, indicating that 
previously unacknowledged challenges of lipoprotein interference on FC-based EV 
analysis on blood plasma may with advantage be taken into consideration in that 
connection. 
It may be possible to refine our described bead procedure with regard to choice of 
antibody clones, incubation periods, and washing steps in order to remove 
lipoproteins and protein aggregrates without introducing a considerable EV loss. To 
broaden the range of methods that could be applied for EV counting upon 
lipoprotein removal to include e.g. FC and TRPS, it would be necessary to design a 
procedure enabling effective lipoprotein removal from plasma diluted less than 
1:400. Regarding TRPS, however, in our experience it would also be necessary to 
improve the robustness of the method in order to apply it for routine use on plasma 
samples. 
Study 4 of this PhD project is the first study to investigate levels of TF-bearing EVs in 
AF patients. There is an increasing focus on distinction between patients who do and 
do not require oral anticoagulation109 and on elucidation of which anticoagulation 
strategies suit different subgroups of AF patients best223. Blood plasma biomarkers 
may hold potential as a supplement to the CHA2DS2-VASc score. While vWF levels 
have been demonstrated to provide some additional prognostic information with 
regard to cardiovascular events and mortality, the absolute impact on decision-
making was considered too small to prioritize inclusion of vWF measurements in the 
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strategy for risk prediction224. Study 4 substantiated the finding by Chung et al.102 on 
elevated levels of blood-borne TF in AF patients and, for the first time, indicated 
elevated levels of TF-bearing EVs, including CD14-positive TF-bearing EVs in AF 
patients. As procoagulant capacity of these EVs may play a mechanistic role in 
thrombogenicity in AF patients, TF-bearing EVs may represent relevant candidates 
for exploration in prospective studies evaluating their potential as predictors of 
thromboembolic events in AF patients. Moreover, TF-positive EVs have been 
suggested as potential targets for future anticoagulants48. Our data suggest that AF 
patients may represent a group, which could benefit from such therapeutic 
advancement. 
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ENGLISH SUMMARY 
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly increases 
the risk of thrombus formation in the left atrial appendage (LAA) of the heart and 
subsequent thromboembolism. The mechanisms by which AF promotes thrombus 
formation include local blood stasis in the LAA, while inflammatory processes and 
elevated blood levels of procoagulant molecules may also be involved. In recent 
years, extracellular vesicles (EVs) have been increasingly considered as potential 
prothrombotic agents. EVs are lipid bilayer membrane-bounded particles released 
from various cell types as a response to physiological or pathological stimuli. The 
external membrane of an EV can facilitate accumulation of blood coagulation factors 
and, furthermore, it can contain tissue factor (TF), the principal initiator of blood 
clotting. Measurement and characterization of EVs in the blood is challenging as they 
are delicate and heterogenous analytes, coexisting with other blood components, 
such as lipoproteins, that may interfere with the analysis. In the four studies included 
in this PhD thesis, methods for EV detection and characterization were tested, 
addressing preanalytical and analytical challenges with a particular focus on 
interference from lipoproteins. Furthermore, venous and LAA blood levels of 
components with a thrombogenic potential, including TF-bearing extracellular 
vesicles, were evaluated in a group of AF patients and a control group.  
In study 1, we found acceptable analytical performance of two methods for particle 
counting, namely nanoparticle tracking analysis and tunable resistive pulse sensing. 
Appreciable inter- and intra-individual variation in particle concentration and mean 
particle size in platelet free plasma (PFP) from healthy individuals was observed. 
Particle concentration and size distribution were affected by a freeze-thaw cycle and, 
more markedly, by food intake, probably due to appearance of lipoproteins in the 
postprandial state. Study 2 showed that it was possible to remove lipoproteins from 
diluted PFP by application of anti-apolipoprotein B antibody-coated magnetic beads. 
However, this ‘bead procedure’ also reduced the EV content as semiquantified by EV 
Array, which is a protein microarray-based method for EV analysis. In study 3, we 
demonstrated that plasma content of lipoproteins and, accordingly, prandial state 
affected flow cytometry measurements of particles staining positive for TF as well as 
for general and cell type specific EV markers, which indicates problematics of 
equating these particles with EVs. On the other hand, EV content as measured by EV 
Array was not affected by food intake. In study 4, we found elevated blood levels of 
TF antigen in AF patients compared to controls, which was in line with a previous 
study. A novel finding in our study was higher levels of TF-bearing EVs, including TF-
bearing EVs of the monocyte-macrophage lineage, in AF patients than in controls as 
measured by EV Array. No differences between venous and LAA blood composition 
were detected. The results indicate that AF-related release of TF-bearing EVs at least 
partially explains the increased levels of circulating TF in AF patients. TF-bearing EVs 
may play a role in the increased thrombogenicity in AF patients and may hold 
potential as predictive markers of AF-related thromboembolism and as targets of 
future anticoagulants for the benefit of AF patients. 
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DANSK RESUMÉ 
Atrieflimren (AF) er en hyppigt forekommende hjerterytmeforstyrrelse, som øger 
risikoen for trombose i hjertets venstre aurikel og tromboembolisme markant. En 
kendt mekanisme bag trombedannelsen er stase af blodet i venstre aurikel, mens 
inflammatoriske processer og øget koncentration af prokoagulante komponenter i 
blodet er mulige medvirkende årsager. I disse år er der stigende opmærksomhed på 
ekstracellulære vesikler (EV) som potentielle trombogene faktorer. EV er partikler 
med en dobbeltlaget lipidmembran, der udskilles af forskellige celletyper som 
respons på fysiologiske eller patologiske stimuli. Blodets koagulationsfaktorer kan 
komme i indbyrdes kontakt på overfladen af vesikelmembranen, som desuden kan 
indeholde proteinet tissue factor (TF), som er den primære initiator af 
koagulationskaskaden. Måling og karakteristik af EV i blodet er kompliceret pga. 
vesiklernes skrøbelighed og heterogenitet samt tilstedeværelsen af interfererende 
blodkomponenter som for eksempel lipoproteiner. I dette ph.d.-projekt, som 
omfatter fire studier, evaluerede vi metoder til måling og karakteristik af EV med 
vægt på problematikken vedrørende interferens fra lipoproteiner. Desuden 
sammenlignede vi niveauerne af en række potentielt trombogene komponenter, 
herunder TF-bærende EV, i veneblod samt i blod udtrukket fra venstre aurikel i en 
gruppe AF-patienter og en kontrolgruppe. 
I studie 1 fandt vi en acceptabel analytisk præcision for to forskellige metoder til 
partikeltælling betegnet henholdsvis nanoparticle tracking analysis og tunable 
resistive pulse sensing. Desuden fandt vi en betydelig inter- og intraindividuel 
variation i partikelkoncentration og middelpartikelstørrelse i blodplasma hos raske 
personer. Partikelkoncentrationen og -størrelsesfordelingen var påvirkelig af 
frysning af plasma før analyse og mere markant påvirkelig af fødeindtag, 
sandsynligvis pga. en øget postprandial koncentration af lipoproteiner. I studie 2 
viste vi, at lipoproteiner kan fjernes fra fortyndet plasma vha. magnetiske partikler 
med antistoffer mod apolipoprotein B, men også at denne procedure reducerer EV-
indholdet i plasma målt med EV Array, som er en protein microarray-baseret metode 
til EV-semikvantificering. I studie 3 demonstrerede vi, at plasmas indhold af 
lipoproteiner påvirker flowcytometriske målinger af partikler med positivt signal for 
TF og for generelle og cellespecifikke EV-markører, hvilket gør det problematisk at 
anvende disse målinger til kvantificering af EV. EV-semikvantificering vha. EV Array 
blev derimod ikke påvirket af fødeindtag. I studie 4 fandt vi, i lighed med et tidligere 
studie, at AF-patienter havde højere plasmakoncentration af TF end 
kontrolpatienter. Desuden fandt vi, at AF-patienter havde et større indhold af TF-
bærende EV i blodet, herunder TF-bærende EV deriveret fra monocyt-makrofag-
cellelinjen, hvilket ikke tidligere er beskrevet. Vi fandt ikke forskelle mellem vene- og 
aurikelblod. Resultaterne indikerer, at AF-relateret frigivelse af TF-bærende EV er 
medvirkende årsag til en øget koncentration af cirkulerende TF hos AF-patienter. TF-
bærende EV er en mulig medvirkende faktor i AF-relateret trombogenicitet og kan 
have potentiale som prædiktiv markør for tromboembolisme og som angrebsmål for 
fremtidige antikoagulantia til AF-patienter. 
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ABBREVIATIONS 
ADP adenosine diphosphate 
AF atrial fibrillation 
ApoA-I apolipoprotein A-I 
ApoB apolipoprotein B 
asTF alternatively spliced tissue factor 
ATP adenosine triphosphate 
CD cluster of differentiation 
CV coefficient of variation 
DNA deoxyribonucleic acid 
DOAC direct oral anticoagulant 
DPBS Dulbecco’s Phosphate Buffered Saline  
ECG electrocardiography 
EPCR endothelial cell protein C receptor 
ESC European Society of Cardiology 
ESCRT endosomal sorting complex required for transport 
EV extracellular vesicle 
FC flow cytometry 
FC region fragment crystallizable region 
FII coagulation factor II 
FIII coagulation factor III 
FIX coagulation factor IX 
flTF full-length tissue factor 
FSC forward scatter 
FV coagulation factor V 
FVII coagulation factor VII 
FVIII coagulation factor VIII 
FX coagulation factor X 
FXI coagulation factor XI 
FXII coagulation factor XII 
FXIII coagulation factor XIII 
GP glycoprotein 
HDL high density lipoprotein 
IDL intermediate density lipoprotein 
ILV intraluminal vesicle 
ISAC International Society on Advancement of Cytometry 
ISEV International Society of Extracellular Vesicles 
LA left atrium 
LDL low density lipoprotein 
LPL lipoprotein lipase 
LPS lipopolysaccharide 
LAA left atrial appendage 
MV microvesicle 
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MVB multivesiclar body 
NET neutrophil extracellular trap 
NO nitric oxide 
NTA nanoparticle tracking analysis 
OAC oral anticoagulant therapy 
PAI-1 plasminogen activator inhibitor-1 
PAI-2 plasminogen activator inhibitor-2 
PE phycoerythrin 
PFP platelet free plasma 
PPL procoagulant phospholipid 
PPL-CT procoagulant phospholipid dependent clotting time  
PS phosphatidylserine 
PSGL-1 P-selectin glycoprotein-1 
RNA ribonucleic acid 
RAA right atrial appendage 
SEC size exclusion chromatography 
SSC side scatter 
TAFI thrombin activated fibrinolysis inhibitor 
TEM tetraspanin-enriched microdomain 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TG triglyceride 
TM thrombomodulin 
TNF-α tumor necrosis factor alpha 
tPA tissue plasminogen activator 
TRL Triglyceride-rich lipoprotein 
TRPS tunable resistive pulse sensing 
TXA2 thromboxane A2 
uPA urokinase type plasminogen activator 
VEGF vascular endothelial growth factor 
VKA vitamin K antagonist 
VLDL very low density lipoprotein 
vWF von Willebrand factor 
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Atrial fibrillation is a prevalent cardiac arrhythmia that significantly increases 
the risk of thrombus formation in the left atrial appendage of the heart and 
subsequent thromboembolism. The mechanisms by which atrial fibrillation 
promotes thrombus formation may involve elevated blood levels of procoag-
ulant molecules. In recent years, extracellular vesicles have attracted grow-
ing attention as potential prothrombotic agents. Extracellular vesicles are 
lipid bilayer membrane-bounded particles released from cells as a response 
to physiological or pathological stimuli. Extracellular vesicles can facilitate 
accumulation of blood coagulation factors and they can contain tissue factor, 
the principal initiator of blood clotting. Measurement of extracellular vesi-
cles in blood is challenging as they are delicate and heterogenous analytes, 
coexisting with other blood components that may interfere with the analysis. 
In this PhD project, methods for extracellular vesicle detection and character-
ization were tested, addressing preanalytical and analytical challenges with a 
particular focus on interference from lipoproteins. Furthermore, venous and 
left atrial appendage blood levels of components with a thrombogenic po-
tential, including tissue factor-bearing extracellular vesicles, were evaluated 
in a group of atrial fibrillation patients and a control group.
